CN113226277B - Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation - Google Patents
Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation Download PDFInfo
- Publication number
- CN113226277B CN113226277B CN201980086762.9A CN201980086762A CN113226277B CN 113226277 B CN113226277 B CN 113226277B CN 201980086762 A CN201980086762 A CN 201980086762A CN 113226277 B CN113226277 B CN 113226277B
- Authority
- CN
- China
- Prior art keywords
- component
- phosphatidylinositol
- polyoxyethylene
- components
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 110
- 239000002537 cosmetic Substances 0.000 title claims abstract description 71
- 230000003834 intracellular effect Effects 0.000 title abstract description 40
- 239000003795 chemical substances by application Substances 0.000 title abstract description 38
- 238000004519 manufacturing process Methods 0.000 title abstract description 37
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract description 36
- 229920002674 hyaluronan Polymers 0.000 title abstract description 36
- 229960003160 hyaluronic acid Drugs 0.000 title abstract description 36
- 230000002087 whitening effect Effects 0.000 title abstract description 28
- 230000037319 collagen production Effects 0.000 title abstract description 27
- 229940123973 Oxygen scavenger Drugs 0.000 title abstract description 13
- -1 complex Substances 0.000 title description 202
- 230000037303 wrinkles Effects 0.000 title description 20
- 230000007794 irritation Effects 0.000 title description 7
- 150000003905 phosphatidylinositols Chemical class 0.000 claims abstract description 159
- 239000000203 mixture Substances 0.000 claims abstract description 125
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000000787 lecithin Substances 0.000 claims abstract description 55
- 235000010445 lecithin Nutrition 0.000 claims abstract description 55
- 229940067606 lecithin Drugs 0.000 claims abstract description 52
- 239000003960 organic solvent Substances 0.000 claims abstract description 43
- 229930182558 Sterol Natural products 0.000 claims abstract description 20
- 235000003702 sterols Nutrition 0.000 claims abstract description 20
- 150000003432 sterols Chemical class 0.000 claims abstract description 18
- 239000006185 dispersion Substances 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000002131 composite material Substances 0.000 claims description 26
- 102000011720 Lysophospholipase Human genes 0.000 claims description 22
- 108020002496 Lysophospholipase Proteins 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 230000001376 precipitating effect Effects 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 239000007858 starting material Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 56
- 229920005862 polyol Polymers 0.000 abstract description 28
- 150000003077 polyols Chemical class 0.000 abstract description 28
- 239000003638 chemical reducing agent Substances 0.000 abstract description 9
- 238000003756 stirring Methods 0.000 description 64
- 238000002156 mixing Methods 0.000 description 49
- 239000000243 solution Substances 0.000 description 46
- 235000014113 dietary fatty acids Nutrition 0.000 description 41
- 229930195729 fatty acid Natural products 0.000 description 41
- 239000000194 fatty acid Substances 0.000 description 41
- 230000000694 effects Effects 0.000 description 39
- 150000002148 esters Chemical class 0.000 description 38
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 34
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 34
- 239000001301 oxygen Substances 0.000 description 34
- 229910052760 oxygen Inorganic materials 0.000 description 34
- 239000007788 liquid Substances 0.000 description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 31
- 238000011156 evaluation Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 30
- 239000006210 lotion Substances 0.000 description 26
- 238000001816 cooling Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 241000196324 Embryophyta Species 0.000 description 19
- 230000001737 promoting effect Effects 0.000 description 19
- 229930006000 Sucrose Natural products 0.000 description 18
- 235000010323 ascorbic acid Nutrition 0.000 description 18
- 239000011668 ascorbic acid Substances 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 18
- 239000005720 sucrose Substances 0.000 description 18
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 14
- 150000003904 phospholipids Chemical class 0.000 description 14
- 239000012981 Hank's balanced salt solution Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 229940072107 ascorbate Drugs 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 150000004665 fatty acids Chemical group 0.000 description 11
- 230000001766 physiological effect Effects 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 10
- 230000002000 scavenging effect Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 229940015975 1,2-hexanediol Drugs 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 9
- 244000068988 Glycine max Species 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 9
- 230000003020 moisturizing effect Effects 0.000 description 9
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 108010022452 Collagen Type I Proteins 0.000 description 8
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 8
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 8
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- KBEFBSGNGSLHOD-UHFFFAOYSA-N 4-methylpentane-1,1-diol Chemical compound CC(C)CCC(O)O KBEFBSGNGSLHOD-UHFFFAOYSA-N 0.000 description 7
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 7
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 244000020551 Helianthus annuus Species 0.000 description 7
- 235000003222 Helianthus annuus Nutrition 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 235000017471 coenzyme Q10 Nutrition 0.000 description 7
- 229940110767 coenzyme Q10 Drugs 0.000 description 7
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 210000001339 epidermal cell Anatomy 0.000 description 7
- 239000007850 fluorescent dye Substances 0.000 description 7
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 7
- 235000019136 lipoic acid Nutrition 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 229960002663 thioctic acid Drugs 0.000 description 7
- 229930003799 tocopherol Natural products 0.000 description 7
- 239000011732 tocopherol Substances 0.000 description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 240000002791 Brassica napus Species 0.000 description 6
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241000628997 Flos Species 0.000 description 6
- 229920006197 POE laurate Polymers 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 229940107161 cholesterol Drugs 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 235000013824 polyphenols Nutrition 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 229960001295 tocopherol Drugs 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical compound CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 5
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 241000736199 Paeonia Species 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 5
- 235000021466 carotenoid Nutrition 0.000 description 5
- 150000001747 carotenoids Chemical class 0.000 description 5
- 150000005690 diesters Chemical class 0.000 description 5
- 235000013345 egg yolk Nutrition 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000002453 shampoo Substances 0.000 description 5
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 5
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 4
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 4
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical class OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 4
- AVBJHQDHVYGQLS-AWEZNQCLSA-N (2s)-2-(dodecanoylamino)pentanedioic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O AVBJHQDHVYGQLS-AWEZNQCLSA-N 0.000 description 4
- 229940083957 1,2-butanediol Drugs 0.000 description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 4
- 229940035437 1,3-propanediol Drugs 0.000 description 4
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 4
- 229940120155 3-o-ethyl ascorbate Drugs 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 239000004386 Erythritol Substances 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 4
- 150000000996 L-ascorbic acids Chemical class 0.000 description 4
- 239000005639 Lauric acid Substances 0.000 description 4
- 244000246386 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 235000004357 Mentha x piperita Nutrition 0.000 description 4
- 235000006484 Paeonia officinalis Nutrition 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 235000004347 Perilla Nutrition 0.000 description 4
- 244000124853 Perilla frutescens Species 0.000 description 4
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 4
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- 241000179532 [Candida] cylindracea Species 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000005215 alkyl ethers Chemical class 0.000 description 4
- KQZNFGJQTPAURD-NBWQQBAWSA-N ascorbyl dipalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)C(O)=C1O KQZNFGJQTPAURD-NBWQQBAWSA-N 0.000 description 4
- 229940067599 ascorbyl glucoside Drugs 0.000 description 4
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 4
- 229940009714 erythritol Drugs 0.000 description 4
- 235000019414 erythritol Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- JJOJFIHJIRWASH-UHFFFAOYSA-N icosanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCCCC(O)=O JJOJFIHJIRWASH-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 4
- 230000003061 melanogenesis Effects 0.000 description 4
- QMHBZWNZCSNBGU-UHFFFAOYSA-N nonane-1,2,3-triol Chemical compound CCCCCCC(O)C(O)CO QMHBZWNZCSNBGU-UHFFFAOYSA-N 0.000 description 4
- 229960002446 octanoic acid Drugs 0.000 description 4
- 229940049964 oleate Drugs 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 4
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 4
- 229930003802 tocotrienol Natural products 0.000 description 4
- 239000011731 tocotrienol Substances 0.000 description 4
- 235000019148 tocotrienols Nutrition 0.000 description 4
- 229960000401 tranexamic acid Drugs 0.000 description 4
- 150000005691 triesters Chemical class 0.000 description 4
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 3
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 3
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 3
- 241001133760 Acoelorraphe Species 0.000 description 3
- 235000017060 Arachis glabrata Nutrition 0.000 description 3
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 description 3
- 235000018262 Arachis monticola Nutrition 0.000 description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 3
- 240000006891 Artemisia vulgaris Species 0.000 description 3
- 235000021357 Behenic acid Nutrition 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 240000003538 Chamaemelum nobile Species 0.000 description 3
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 3
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 3
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 3
- 229920002079 Ellagic acid Polymers 0.000 description 3
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 235000000060 Malva neglecta Nutrition 0.000 description 3
- 240000000982 Malva neglecta Species 0.000 description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 229920006200 POE myristate Polymers 0.000 description 3
- 241000228143 Penicillium Species 0.000 description 3
- 240000000064 Penicillium roqueforti Species 0.000 description 3
- 235000002233 Penicillium roqueforti Nutrition 0.000 description 3
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Polymers CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 description 3
- 240000002657 Thymus vulgaris Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940116226 behenic acid Drugs 0.000 description 3
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 229940099417 ceramide 2 Drugs 0.000 description 3
- 229940044176 ceramide 3 Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960002852 ellagic acid Drugs 0.000 description 3
- 235000004132 ellagic acid Nutrition 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 229940101267 panthenol Drugs 0.000 description 3
- 235000020957 pantothenol Nutrition 0.000 description 3
- 239000011619 pantothenol Substances 0.000 description 3
- 235000020232 peanut Nutrition 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229960000342 retinol acetate Drugs 0.000 description 3
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 3
- 235000019173 retinyl acetate Nutrition 0.000 description 3
- 239000011770 retinyl acetate Substances 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 235000015500 sitosterol Nutrition 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000037072 sun protection Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000001585 thymus vulgaris Substances 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 2
- MBZYKEVPFYHDOH-UHFFFAOYSA-N (10S)-3c-Hydroxy-4.4.10r.13t.14c-pentamethyl-17t-((R)-1.5-dimethyl-hexyl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21C MBZYKEVPFYHDOH-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 2
- RUHCWQAFCGVQJX-RVWHZBQESA-N (3s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-1-one Chemical compound C1C=C2C[C@H](O)CC(=O)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RUHCWQAFCGVQJX-RVWHZBQESA-N 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 2
- 229940031723 1,2-octanediol Drugs 0.000 description 2
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 2
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- MBZYKEVPFYHDOH-BQNIITSRSA-N 24,25-dihydrolanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@]21C MBZYKEVPFYHDOH-BQNIITSRSA-N 0.000 description 2
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 2
- ALHUZKCOMYUFRB-UHFFFAOYSA-N 3-methylcyclopentadecan-1-one Chemical compound CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 2
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 2
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000722941 Achillea Species 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 241001105098 Angelica keiskei Species 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 2
- 235000005340 Asparagus officinalis Nutrition 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 2
- 240000006248 Broussonetia kazinoki Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 235000005747 Carum carvi Nutrition 0.000 description 2
- 240000000467 Carum carvi Species 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 240000001980 Cucurbita pepo Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 240000001972 Gardenia jasminoides Species 0.000 description 2
- 239000005792 Geraniol Substances 0.000 description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 2
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 241000219146 Gossypium Species 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 235000018081 Hibiscus syriacus Nutrition 0.000 description 2
- 244000130592 Hibiscus syriacus Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 102100032241 Lactotransferrin Human genes 0.000 description 2
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 2
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000021360 Myristic acid Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 241000218657 Picea Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 244000173853 Sanguisorba officinalis Species 0.000 description 2
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241001530209 Swertia Species 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 241001506047 Tremella Species 0.000 description 2
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 description 2
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 2
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 2
- UEYVMVXJVDAGBB-ZHBLIPIOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl tetradecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O UEYVMVXJVDAGBB-ZHBLIPIOSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 2
- 235000004420 brassicasterol Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 229940095137 ceramide 6 ii Drugs 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- YSRSBDQINUMTIF-UHFFFAOYSA-N decane-1,2-diol Chemical compound CCCCCCCCC(O)CO YSRSBDQINUMTIF-UHFFFAOYSA-N 0.000 description 2
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 229940093476 ethylene glycol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 229940113087 geraniol Drugs 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- HXYCHJFUBNTKQR-UHFFFAOYSA-N heptane-1,2,3-triol Chemical compound CCCCC(O)C(O)CO HXYCHJFUBNTKQR-UHFFFAOYSA-N 0.000 description 2
- GCXZDAKFJKCPGK-UHFFFAOYSA-N heptane-1,2-diol Chemical compound CCCCCC(O)CO GCXZDAKFJKCPGK-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229940058690 lanosterol Drugs 0.000 description 2
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940059574 pentaerithrityl Drugs 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- AALKGALVYCZETF-UHFFFAOYSA-N pentane-1,2,3-triol Chemical compound CCC(O)C(O)CO AALKGALVYCZETF-UHFFFAOYSA-N 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 235000002378 plant sterols Nutrition 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229940051841 polyoxyethylene ether Drugs 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000012144 protein assay dye reagent concentrate Substances 0.000 description 2
- 125000001453 quaternary ammonium group Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- JYKSTGLAIMQDRA-UHFFFAOYSA-N tetraglycerol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO JYKSTGLAIMQDRA-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 150000004072 triols Chemical class 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N 1,4-Benzenediol Natural products OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- LQXBZWFNAKZUNM-UHFFFAOYSA-N 16-methyl-1-(16-methylheptadecoxy)heptadecane Chemical compound CC(C)CCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC(C)C LQXBZWFNAKZUNM-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- MLRIJUWUQTVDQE-UHFFFAOYSA-N 2-phenylethyl-O-beta-D-galactoside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=CC=C1 MLRIJUWUQTVDQE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 description 1
- BUUSNVSJZVGMFY-UHFFFAOYSA-N 4-ethylheptane-3,3-diol Chemical compound CCCC(CC)C(O)(O)CC BUUSNVSJZVGMFY-UHFFFAOYSA-N 0.000 description 1
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 description 1
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 235000002672 Artocarpus altilis Nutrition 0.000 description 1
- 240000004161 Artocarpus altilis Species 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 235000003884 Aspalathus contaminatus Nutrition 0.000 description 1
- 235000012984 Aspalathus linearis Nutrition 0.000 description 1
- 240000006914 Aspalathus linearis Species 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 235000010082 Averrhoa carambola Nutrition 0.000 description 1
- 240000006063 Averrhoa carambola Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000006506 Brasenia schreberi Nutrition 0.000 description 1
- 244000267222 Brasenia schreberi Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000288570 Chionochloa conspicua Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 235000021513 Cinchona Nutrition 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000003913 Coccoloba uvifera Nutrition 0.000 description 1
- 240000009212 Coccoloba uvifera Species 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 241000233838 Commelina Species 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 244000016281 Cymbalaria muralis Species 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 241000735527 Eupatorium Species 0.000 description 1
- 235000007270 Gaultheria hispida Nutrition 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 241000208681 Hamamelis virginiana Species 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 235000015916 Hydrocotyle vulgaris Nutrition 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 240000000917 Impatiens balsamina Species 0.000 description 1
- 235000015912 Impatiens biflora Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 244000108452 Litchi chinensis Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 244000182807 Mentha suaveolens Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 244000269152 Myrica pensylvanica Species 0.000 description 1
- 235000012851 Myrica pensylvanica Nutrition 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241001295692 Pyracantha fortuneana Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 241000272503 Sparassis radicata Species 0.000 description 1
- 235000005116 Stachys sieboldii Nutrition 0.000 description 1
- 244000057214 Stachys sieboldii Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000907897 Tilia Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 241000196252 Ulva Species 0.000 description 1
- 244000081822 Uncaria gambir Species 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 244000003892 Vaccinium erythrocarpum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- JWRQVQWBNRGGPK-JZYAIQKZSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(OC)=CC(C=CC(=O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 JWRQVQWBNRGGPK-JZYAIQKZSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- HLLPKVARTYKIJB-MCQPFKOBSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O1 HLLPKVARTYKIJB-MCQPFKOBSA-N 0.000 description 1
- NJWPTAJOXLJZHJ-XQAXEFKXSA-N [(2s,3s,4r,5r)-3,4-di(dodecanoyloxy)-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl dodecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCC)O[C@H](CO)[C@@H](OC(=O)CCCCCCCCCCC)[C@@H]1OC(=O)CCCCCCCCCCC NJWPTAJOXLJZHJ-XQAXEFKXSA-N 0.000 description 1
- OCRUMFQGIMSFJR-FSAWCSQFSA-N [(2s,3s,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-[(z)-octadec-9-enoyl]oxy-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC OCRUMFQGIMSFJR-FSAWCSQFSA-N 0.000 description 1
- VFCBYFDYBODXCH-YGWGHPONSA-N [(2s,3s,4r,5r)-5-(hydroxymethyl)-3,4-bis[[(z)-octadec-9-enoyl]oxy]-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC VFCBYFDYBODXCH-YGWGHPONSA-N 0.000 description 1
- FUAVHLIMXAIRGA-AFRRYHNSSA-N [(2s,3s,4r,5r)-5-(hydroxymethyl)-3,4-di(tetradecanoyloxy)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl tetradecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCC)O[C@H](CO)[C@@H](OC(=O)CCCCCCCCCCCCC)[C@@H]1OC(=O)CCCCCCCCCCCCC FUAVHLIMXAIRGA-AFRRYHNSSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 229940033280 alpha-arbutin Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JNFDQAYPZCYWLD-UHFFFAOYSA-N bis[2-(2-ethoxyethoxy)ethyl] cyclohexane-1,4-dicarboxylate Chemical compound CCOCCOCCOC(=O)C1CCC(C(=O)OCCOCCOCC)CC1 JNFDQAYPZCYWLD-UHFFFAOYSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 239000001599 crocus sativus l. flower extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 229960005082 etohexadiol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 229940075999 phytosterol ester Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 244000276444 pluma Species 0.000 description 1
- 235000019129 pluma Nutrition 0.000 description 1
- 235000019070 pluma del Caribe Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 229940076591 saffron extract Drugs 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- ZWZWYGMENQVNFU-UHNVWZDZSA-N sn-glycero-3-phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(=O)OC[C@H](O)CO ZWZWYGMENQVNFU-UHNVWZDZSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- IEMIRSXOYFWPFD-UHFFFAOYSA-N trans-ferulic acid beta-D-glucopyranoside Natural products COC1=CC(C=CC(O)=O)=CC=C1OC1C(O)C(O)C(O)C(CO)O1 IEMIRSXOYFWPFD-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229940093633 tricaprin Drugs 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a new application of phosphatidylinositol. And provides a composition capable of simply and stably dispersing phosphatidylinositol in water and a technique for simply and stably dispersing phosphatidylinositol in water. Phosphatidylinositol (PI), in particular, a high-concentration PI composition produced by a specific method can be used as a whitening agent, a hyaluronic acid production promoter, a collagen production promoter, an intracellular active oxygen scavenger, a irritation-reducing agent, and a wrinkle-improving agent. The technical problem of the present invention can be solved by removing the organic solvent from a solution in which the component (A1) phosphatidylinositol, the component (A2) lecithin and the component (A3) sterols are uniformly dissolved in the organic solvent to obtain a complex in which the components (A1) to (A3) are simultaneously precipitated, and a cosmetic or skin external preparation containing the component (a) composition containing phosphatidylinositol and lecithin, the component (B) polyol and the component (C) water as essential components.
Description
Technical Field
The present invention relates to a phosphatidylinositol-containing whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation-reducing agent, wrinkle-improving agent, complex, cosmetic, and external preparation for skin.
Background
Lecithin is a generic term for glycerophospholipids obtained from animals or plants, and is widely used as a natural emulsifier in foods, cosmetics, pharmaceuticals, and the like. The constituent components of lecithin are classified according to the structure of a polar group bonded to a phosphate group, and phosphatidylcholine (hereinafter, also simply referred to as PC.), phosphatidylethanolamine (hereinafter, also simply referred to as PE.), phosphatidylserine (hereinafter, also simply referred to as PS.), phosphatidylinositol (hereinafter, also simply referred to as PI.), phosphatidic acid (hereinafter, also simply referred to as PA.), and the like are known as main components. In recent years, studies have been made focusing on various functions and effects of these, and among them, PI is known to be closely related to an intracellular and extracellular information transfer function, and physiological actions of reducing triglyceride concentration in blood and increasing HDL cholesterol by taking PI have been reported. In addition, physiological actions such as an increase in hyaluronic acid of skin (patent document 1) and an increase in Nrf2 activity (patent document 2) have also been reported, but the physiological actions of PI have not been sufficiently studied yet.
When PI is used as an active ingredient for various applications, it is important to obtain a composition containing PI at a high concentration, and as a method for this, a method of separating fractionated lecithin by solvent separation (for example, patent document 3) and column purification has been conventionally used, but there are problems in terms of complicated production and cost. Meanwhile, recently, a method for efficiently producing PI using a phospholipase having substrate specificity that does not substantially act on PI but specifically acts on phospholipids other than PI has been developed (patent documents 4 and 5). According to this method, a composition containing PI at a high concentration can be industrially obtained at low cost. Patent document 4 describes that a composition containing PI at a high concentration obtained by the method can be used in foods, pharmaceuticals or cosmetics, but the function thereof has not been sufficiently studied, and it has been limited to food use at the present stage.
In general, although a method of using a polyoxyethylene surfactant or the like in combination is known as a method of solving such a problem, for example, in which PI has a poor emulsifying power as compared with other phospholipids (patent document 6), there is a concern about safety and skin irritation of a synthetic surfactant, and a method of not using or reducing the synthetic surfactant is desired. Patent document 7 discloses a lecithin-sterol complex obtained by removing an organic solvent from a solution in which lecithin and sterol are uniformly dissolved in the organic solvent, and precipitating both lecithin and sterol, as a method of dispersing lecithin lacking hydration in water. Patent document 8 discloses a water-insoluble physiologically active substance-phospholipid complex obtained by removing an organic solvent from a solution in which a physiologically active substance and a phospholipid which are insoluble in water are uniformly dissolved in the organic solvent and precipitating the physiologically active substance and the phospholipid at the same time, and the use of the complex can easily emulsify and solubilize the physiologically active substance which is insoluble in water, and the obtained composition has good dispersion stability. However, a complex containing phosphatidylinositol, lecithin and sterols at a specific ratio is not known.
As a technique for dispersing phospholipids in water, a method using a polyol is known (for example, patent documents 9 and 10). However, no technology for dispersing phosphatidylinositol using a polyol is known.
Prior art literature
Patent literature
Patent document 1: international publication No. 2009/110205
Patent document 2: japanese patent application laid-open No. 2011-168641
Patent document 3: japanese patent laid-open No. 60-246305
Patent document 4: international publication No. 2007/010892
Patent document 5: japanese patent application laid-open No. 2015-27260
Patent document 6: japanese patent application laid-open No. 2012-77000
Patent document 7: japanese patent laid-open No. 4-149194
Patent document 8: japanese patent laid-open No. 2007-197328
Patent document 9: japanese patent laid-open No. 60-153938
Patent document 10: japanese patent laid-open No. 11-130651
Disclosure of Invention
Technical problem to be solved by the invention
The technical problem of the invention is to find new physiological effects on phosphatidylinositol and provide new application.
Another object of the present invention is to provide a complex capable of easily dispersing phosphatidylinositol in water.
In addition, the inventors of the present invention found that even in the method using a polyol, the dispersibility of phosphatidylinositol in water is very low in the case of the polyol alone. Accordingly, another technical problem of the present invention is to provide a technique capable of dispersing phosphatidylinositol in water easily and stably.
Technical scheme for solving technical problems
As a result of intensive studies to solve the above-mentioned problems, the inventors of the present invention have found that phosphatidylinositol has various physiologically active actions, and have completed the present invention. In particular, a composition containing phosphatidylinositol at a high concentration obtained by a method comprising a predetermined step has an extremely excellent physiologically active effect.
Namely, the present invention provides the following whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation-relieving agent, wrinkle-improving agent, complex, cosmetic and external preparation for skin.
Item 1.
A whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation-relieving agent or wrinkle-improving agent containing phosphatidylinositol.
Item 2.
The agent according to claim 1, wherein the phosphatidylinositol is obtained by a method comprising the steps (1) to (3) in this order, and the agent is a composition containing 40 to 75% by weight of phosphatidylinositol,
(1): a step of allowing a phosphatidylinositol-free substrate-specific phospholipase B to act on lecithin;
(2): extracting phosphatidylinositol with an organic solvent;
(3): and a step of precipitating and recovering phosphatidylinositol using a hydrophilic solvent.
Item 3.
The agent according to item 2, wherein,
the phospholipase B is derived from Candida cylindracea (Candida cylindracea), penicillium shamen (Penicillium camanbertti), penicillium roqueforti (Penicillium Roqueforti), or Rhizopus oryzae (Rhizu oryzae).
Item 4.
A composite, characterized in that:
for preparing an emulsified or solubilized composition, wherein the composition is obtained by removing an organic solvent from a dispersion or solution in which the following components (A1) to (A3) are uniformly dispersed or dissolved in the organic solvent, and simultaneously precipitating the components (A1) to (A3);
(A1) Phosphatidylinositol,
(A2) Lecithin (L),
(A3) Sterols.
Item 5.
The complex according to item 4, wherein,
the component (A1) is a composition containing 40 to 75% by weight of phosphatidylinositol obtained by a method comprising the following steps (1) to (3) in this order,
(1): a step of allowing a phosphatidylinositol-free substrate-specific phospholipase B to act on lecithin;
(2): extracting phosphatidylinositol with an organic solvent;
(3): and a step of precipitating and recovering phosphatidylinositol using a hydrophilic solvent.
Item 6.
The complex according to item 4 or 5, wherein,
the component (A2) is lecithin having a phosphatidylcholine content of 50 to 99% by weight.
Item 7.
The complex according to any one of claim 4 to 6, wherein,
the component (A2) is a mixture of hydrogenated lecithin and non-hydrogenated lecithin.
Item 8.
The complex according to any one of claim 4 to 7, wherein,
the total content of the components (A1) and (A2) in the composite is 60 to 99 wt%,
the content of the component (A3) is 1 to 40% by weight, and,
the weight ratio of the components (A1) to (A2) is 5: 95-50: 50.
item 9.
The complex according to any one of claim 4 to 7, wherein,
also contains antioxidant substances as component (A4),
the complex is obtained by removing the organic solvent from a dispersion or solution in which the components (A1) to (A4) are uniformly dispersed or dissolved in the organic solvent to simultaneously precipitate the components (A1) to (A4),
the total content of the components (A1) and (A2) in the composite is 40 to 98.99 wt%, the content of the component (A3) is 1 to 40 wt%, the content of the component (A4) is 0.01 to 20 wt%, and the weight ratio of the components (A1) to (A2) is 5: 95-50: 50.
Item 10.
A cosmetic or skin external preparation comprising the complex according to any one of claims 4 to 9.
Item 11.
A cosmetic or skin external preparation contains the following components (A) - (C).
(A) A composition comprising the following components (A1) and (A2):
(A1) Phosphatidylinositol,
(A2) Lecithin;
(B) A polyol;
(C) And (3) water.
Item 12.
The cosmetic or dermatological external preparation according to item 11, wherein,
the component (A1) is a composition containing 40 to 75% by weight of phosphatidylinositol obtained by a method comprising the steps (1) to (3) described below in this order.
(1): a step of allowing a phosphatidylinositol-free substrate-specific phospholipase B to act on lecithin;
(2): extracting phosphatidylinositol with an organic solvent;
(3): and a step of precipitating and recovering phosphatidylinositol using a hydrophilic solvent.
Item 13.
The cosmetic or skin external preparation according to item 11 or 12, wherein,
the component (A2) is lecithin having a phosphatidylcholine content of 50 to 99% by weight.
Item 14.
The cosmetic or skin external preparation according to any one of claims 11 to 13, wherein,
the component (A2) is a mixture of hydrogenated lecithin and non-hydrogenated lecithin.
Item 15.
The cosmetic or skin external preparation according to any one of claims 11 to 14, wherein,
As the component (A), a steroid as the component (A3) is also contained.
Item 16.
The cosmetic or skin external preparation according to any one of claims 11 to 15, wherein,
the composition (A) further contains an antioxidant substance as the component (A4).
Item 17.
The cosmetic or skin external preparation according to item 15, wherein,
the component (A) is a complex according to any one of items 4 to 8.
Item 18.
The cosmetic or skin external preparation according to item 16, wherein,
the component (A) is the complex according to item 9.
Item 19.
The cosmetic or dermatological external preparation according to any one of claims 11 to 18, wherein,
the content of the component (A) is 0.001 to 5% by weight, and the weight ratio of the component (A) to the component (B) is 1:5 to 1:200.
item 20.
The cosmetic or skin external preparation according to any one of claims 11 to 19, wherein,
the component (B) contains at least 1 selected from the group consisting of 1, 2-pentanediol, 1, 2-hexanediol, and isohexanediol (hexide).
Item 21.
The cosmetic or skin external preparation according to any one of claims 11 to 20, wherein,
and a nonionic surfactant as component (D).
Item 22.
The cosmetic or dermatological external preparation according to item 21, wherein,
the weight ratio of the components (A) to (D) is 1:0.1 to 1:10.
Item 23.
The cosmetic or dermatological external preparation according to item 21 or 22, wherein,
the component (D) is at least 1 selected from the group consisting of fatty acid glycerides, polyglycerin fatty acid esters, sucrose fatty acid esters, mannitol erythritol esters, polyoxyethylene fatty acid glycerides, polyoxyethylene fatty acid sorbitan esters, polyoxyethylene fatty acid esters, and polyoxyethylene alkyl ethers.
Item 24.
The cosmetic or dermatological external preparation according to any one of claims 11 to 23, which has transparency in appearance.
ADVANTAGEOUS EFFECTS OF INVENTION
Phosphatidylinositol has excellent physiological activities such as whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, intracellular active oxygen scavenging effect, irritation relieving effect and wrinkle improving effect.
In addition, by using the complex of the present invention, phosphatidylinositol can be easily dispersed in water. In addition, the emulsion or dissolvable composition obtained has good dispersion stability. The complex of the present invention can exhibit excellent physiological activities such as whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, intracellular active oxygen scavenging effect, irritation relieving effect, and wrinkle improving effect, and is more surprisingly excellent in effect when used as a complex.
The cosmetic or skin external preparation of the present invention enables easy and stable dispersion of phosphatidylinositol in water.
Drawings
FIG. 1 is a graph showing the wrinkle-improving effect of phosphatidylinositol.
Detailed Description
The present invention relates to a phosphatidylinositol-containing whitening agent, a collagen production promoter, a hyaluronic acid production promoter, an intracellular active oxygen scavenger, a irritation-reducing agent, and a wrinkle-improving agent.
Phosphatidylinositol is 1 kind of phospholipid which is naturally present in plants such as soybean, rapeseed, sunflower, corn, palm, etc., and is contained in lecithin extracted from these plants. In the present invention, such lecithin may be used as it is, or a composition having an increased PI content may be used by solvent separation from such lecithin, column purification, or the use of an enzyme method described later. Specifically, the method using the enzyme includes the following steps (1) to (3).
(1): a step of allowing a phospholipase B having substrate specificity, which does not substantially act on PI, to act on lecithin;
(2): extracting PI with an organic solvent;
(3): and a step of precipitating and recovering the PI using a hydrophilic solvent.
The composition containing Phosphatidylinositol (PI) at a high concentration (hereinafter, simply referred to as a high-concentration PI composition) obtained by the above-described method using an enzyme is obtained by a method comprising the steps (1) to (3), and details thereof will be described below.
Examples of the lecithin used in the step (1) of producing the high-concentration PI composition include natural lecithins obtained from plants such as soybean, rapeseed, sunflower, peanut, cotton seed, corn, rice, barley, and egg yolk, and hydrogenated products thereof. These may be used alone or in combination of 2 or more. Among them, lecithin derived from plants is preferably used, more preferably from soybean or sunflower is used, and most preferably from soybean is used.
The phospholipase B having substrate specificity used in the step (1) of producing the high-concentration PI composition will be described. Phospholipase B (hereinafter also abbreviated as plb.) is a generic term for enzymes having an activity of acting on fatty acids bonded to the α -and β -positions of a glyceryl in glycerophospholipids through ester bonds and hydrolyzing the fatty acids. The PLB used in the present invention preferably has a substrate specificity that does not substantially act on PI but specifically acts on phospholipids such as PC, PE, PS, PA other than PI. As the phospholipase B, enzymes derived from microorganisms such as candida cylindracea described in patent document 4, penicillium salkii, penicillium roquefortii, and rhizopus oryzae described in patent document 5 can be used. Most preferred among these are enzymes derived from candida cylindracea.
In the present specification, a substrate having a substrate specificity that does not substantially act on PI is defined as: when the PLB activity is measured using PI or PC as a substrate, and the activity ratio (relative activity) of PI to PC is determined, the activity ratio is 10% or less, preferably 5% or less. On the other hand, the ratio of activities (relative activities) of phospholipids (PE, PS, PA) other than PI to PC is 20 to 150%, preferably 30 to 100%, which is sufficiently higher than PI. The PLB activity can be measured by the method described in patent document 4.
The conditions for allowing phospholipase B (PLB) to act on lecithin in the step (1) of producing a high-concentration PI composition may be as described in patent document 4 or 5. Specifically, PLB is added in a range of 1000 ~ 100000000 units, more preferably 2000 to 5000000 units per 1kg of lecithin. Lecithin is prepared as an aqueous dispersion previously uniformly dispersed in water, preferably to which PLB is added. As a method of dispersing lecithin in water, for example, a homogenizer or the like is preferably used. The concentration of lecithin in the aqueous dispersion is not particularly limited as long as it can act on PLB, and is in the range of 1 to 20% by weight, preferably 5 to 10% by weight, and particularly preferably 6 to 8% by weight.
The pH at which lecithin and PLB are allowed to act is preferably adjusted to a pH in the range of 3 to 10, more preferably adjusted to a pH around 5.5 to 6.5 at which the activity of PLB is maximized. In this case, in order to maintain the pH constant, a buffer solution is preferably used, and the type of buffer solution is not particularly limited as long as it has a buffer capacity in the range of pH5.5 to 6.5.
In addition, it is also preferable to appropriately add an alkali solution to the reaction instead of using a buffer solution to control the pH of the reaction solution within a preferable range. The temperature conditions in this case may be set within a range in which PLB is not deactivated, and the upper limit is preferably 60℃and more preferably 45 ℃. The lower limit of the temperature conditions under which the action is performed is preferably 10 ℃, more preferably 30 ℃. The reaction time varies depending on the above-mentioned enzyme reaction conditions, and is usually 1 to 150 hours, so long as the residual amount of the substrate can be quantitatively grasped and the reaction can be stopped. After the completion of the reaction, PLB may be deactivated by heat treatment, pH treatment or the like.
By performing the step (1) in the above-described manner, phospholipids such as PC, PE, PS, and PA other than PI in lecithin are selectively hydrolyzed to form free fatty acids, and deacylated phospholipids such as glycerophosphorylcholine (hereinafter also simply referred to as gpc), phosphatidylethanolamine (hereinafter also simply referred to as gpe.), glycerophosphorylserine (hereinafter also simply referred to as gps), and glycerophosphate (hereinafter also simply referred to as gpa). On the other hand, PI can be left as it is without being hydrolyzed.
As the organic solvent used in the step (2) of producing the high-concentration PI composition, at least one selected from chloroform, methylene chloride, toluene, diethyl ether, ethyl acetate, heptane, hexane, and a mixed solution of these with at least one selected from isopropanol, ethanol, and the like can be used. Among them, at least one selected from ethyl acetate, heptane and hexane and a mixed liquid of these and ethanol are more preferable, and hexane or a hexane-ethanol mixed liquid is further preferable.
In the present specification, the extraction of PI in the production process (2) of the high-concentration PI composition is defined as: the above-mentioned organic solvent is added to the reaction solution in the step (1), and the mixture is allowed to stand so as to separate the reaction solution into an organic solvent phase and an aqueous phase, whereby PI remaining in the step (1) is extracted in the organic solvent phase. In this case, it is preferably carried out in the presence of an inorganic salt and/or a chelating agent. In step (2), the free fatty acid, which is the hydrolysis product of step (1), is also soluble in an organic solvent, and is thus extracted in the organic solvent phase. Further hydrolysate GPC, GPE, GPS, GPA and the like are soluble in water, and therefore remain in the aqueous phase, and these components are removed in step (2).
The hydrophilic solvent used in the step (3) of producing the high-concentration PI composition is preferably at least one selected from acetone, isopropyl alcohol, ethanol and methanol, a mixed solution of these with water, and the like, and more preferably acetone and/or ethanol, a mixed solution of these with water, and the like.
Specifically, the process of adding the hydrophilic solvent to the PI-extracted organic solvent solution obtained in the step (2) or the concentrate obtained by recovering the organic solvent from the solution is first performed. PI is insoluble in the above hydrophilic solvent, and thus PI can be precipitated by such an operation. The precipitated PI is separated from the hydrophilic solvent by a method such as filtration or centrifugation, and further dried, whereby the target high-concentration PI composition can be recovered as a powder. In this step, the free fatty acid is soluble in the hydrophilic solvent, and thus the free fatty acid is removed in this step.
The high-concentration PI composition obtained by the above-described procedure can be obtained as a composition containing 40 to 75 wt%, more preferably 45 to 70 wt% PI. Such a production method is more efficient and easier to scale than conventional methods such as solvent separation and column purification, and therefore is most suitable as a method for industrially obtaining a high-concentration PI composition at low cost. In addition to the composition produced by the above-described production method, the high-concentration PI composition used in the present invention is commercially available as Soybrain PI50 (Soybrain PI 50) (manufactured by Unitec Foods) and such a commercially available product can be preferably used in the present invention.
The high-concentration PI composition obtained by the method comprising the steps (1) to (3) also contains components other than PI. Specifically, the inventors of the present invention have found that the components in the composition are separated by column chromatography and analyzed by various analytical instruments, and as a result, they contain about 3 to 10% by weight of sterol glucoside, about 2 to 8% by weight of phosphatidylethanolamine, about 0.1 to 2% by weight of phosphatidic acid, and about 1 to 5% by weight of triglyceride, and further contain about 15 to 35% by weight of unidentified components. Therefore, it is difficult to clearly define all components of the high-concentration PI composition obtained by the method including the steps (1) to (3), and the composition should be defined according to the production method.
As shown in examples described later, phosphatidylinositol has excellent physiological activities such as whitening, collagen production promoting, hyaluronic acid production promoting, intracellular active oxygen scavenging, irritation relieving and wrinkle improving. Therefore, these effects can be utilized as active ingredients of a whitening agent, a collagen production promoter, a hyaluronic acid production promoter, an intracellular active oxygen scavenger, a irritation-reducing agent or a wrinkle-improving agent. Such a physiologically active effect is more excellent in the high-concentration PI composition obtained by the above-described method comprising the steps (1) to (3) than in phosphatidylinositol alone, presumably due to the influence of each component (including unidentified components) other than PI contained in the high-concentration PI composition.
The blending amount of PI in the whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention is not particularly limited, but is preferably 0.01 to 99% by weight, more preferably 0.1 to 90% by weight. The amount to be blended can be appropriately designed depending on the dosage form or the mode of administration.
Examples of methods for administering the whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention to a living body include oral administration, administration by injection, subcutaneous administration and the like. The amount to be administered is not particularly limited as long as the effect of the present invention can be obtained, and may be appropriately adjusted depending on the formulation form, site of application, age, sex, and the like of the preparation.
The whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention may be used as they are, or may be dissolved, dispersed or mixed in a usual base, for example, water, gel, polyol, vaseline, paraffin, vegetable oil, silicone oil or the like. In addition, various additives may be used in combination as needed. The additive that can be used is not particularly limited as long as it is an additive that is generally used to obtain a desired dosage form, and may be used by appropriately selecting known additives such as excipients, colorants, tackifiers, binders, disintegrants, dispersants, stabilizers, gelling agents, antioxidants, surfactants, preservatives, humectants, and pH adjusters. Alternatively, the active ingredient exhibiting the desired effect may be formulated and administered as a component of a pharmaceutical or cosmetic product. In the case of pharmaceuticals, the pharmaceutical composition may be formulated into oral preparations such as tablets, capsules, granules, powders, liquids, suspensions, etc.; external preparations such as skin external preparations, patches, eye drops, nasal drops, oral preparations, and suppositories; the preparation can be formulated into non-oral preparation such as drop and injection. In the case of cosmetics, it can be used in skin cosmetics such as astringent, skin care liquid (conditioner), gel, lotion, skin care liquid, cream, facial mask, facial cleanser, and body cleaner; make-up cosmetics such as foundations, lipsticks, mascara solutions, and the like; hair cosmetics such as shampoo, hair conditioner, hair spray, hair wax, styling lotion, dyeing lotion, hair beautifying agent, and hair tonic are added.
The whitening agent, collagen production promoter, hyaluronic acid production promoter, intracellular active oxygen scavenger, irritation-reducing agent and wrinkle-improving agent of the present invention may be used in combination with a component having the same physiological activity, blood circulation promoter and the like. By combining such components, the effects of the present invention can be synergistically exhibited.
Examples of the whitening agent that can be used in combination include hydroquinone glycoside such as β -arbutin and α -arbutin, and esters thereof; ascorbyl phosphate salts such as ascorbic acid, sodium ascorbyl phosphate, and magnesium ascorbyl phosphate; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexyl glyceryl ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; tranexamic acid, cetyl tranexamic acid, and tranexamic acid amide; polyphenols such as brown algae polyphenols, curcumin, anthocyanin, procyanidine, catechin, ellagic acid, and apple polyphenols; nicotinamide, kojic acid, ellagic acid, 4-methoxysalicylic acid, linoleic acid, ferulic acid, placenta extract, glutathione, oryzanol, butylresorcinol, glabridin, resveratrol, lipoic acid, glucosylceramide, ergothioneine, phyllitol, hinokitiol, cysteine, gentisic acid, mevalonic acid, gallic acid, ornithine, glucosylrutin; and plant extracts having an effect of matricaria, licorice, saxifrage, mulberry, angelica, sanguisorba, paeonia, scutellaria baicalensis, hypericum, polygonum cuspidatum, tea, perilla, peach leaf, snow grass, japanese tripe, aloe, achillea, yarrow, through-leaf eupatorium, kudzu root, arnica, bearberry, asarum, rose fruit, asparagus, platycodon grandiflorum, thyme, horse chestnut, honeysuckle, mugwort, waxberry, raspberry, caraway leaf, cynara scolymus leaf, apricot kernel, lychee seed, broccoli bud, cinchona, polymerized grass, almond, gardenia, kuh-seng, spruce, ophiopogon root, pink pluma, needle cherry, clove, rose, coix seed, tilia, sesame, swertia, rehmannia, peppermint, gentian, caraway, heart, ginger, althea (althea), hyoscyama, grape seed, shrubus, evening primrose seed, kiwi seed and the like.
Specific examples of the collagen production promoter that can be used in combination include ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and other ascorbyl phosphate salts; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexyl glyceryl ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; retinoids such as retinol, retinol acetate, retinol palmitate, hydrogenated retinol, and the like; nicotinamide, glutathione, cysteine, crocetin, sericin, geraniol (geraniol), glyceroglycosides, lactoferrin, procyanidins, pantothenic acid, panthenol, soyasaponin, resveratrol, isoflavones, coenzyme Q10, chondroitin sulfate, acetylglucosamine, glycerophosphorylcholine, hydrolyzed hyaluronic acid, collagen peptides, shell matrix (condhiolin) hydrolysates, 5' adenosine monophosphate, proline, glycine, arginine, aspartic acid, alanine; and plant extracts having collagen production promoting effect, such as hibiscus, licorice leaves, roman chamomile, sweet tea, hawthorn, impatiens balsamina, lotus leaves, kudzu root, sparassis crispa, chlorella, bear's bamboo, burdock, sophorae radix, cabbage heart, loquat leaves, perilla, pea, mulberry leaf, thyme, spruce, basil, dayflower, platycladi seed, cassia seed, snakegourd seed, garden burnet, kuh-seng, persimmon, peony, perilla, dried orange peel, mallow, ginger, chamomile, strawberry seeds, swertia herb, soybean, wheat, ginseng, coix seed, fangku, cardamon, rosemary, sage, and the like.
Examples of the hyaluronic acid production promoter that can be used in combination include ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and other ascorbyl phosphate salts; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexylglycerin ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; retinoids such as retinol, retinol acetate, retinol palmitate, hydrogenated retinol, and the like; nicotinamide, carotenes, tocopherols, tocotrienols, chondroitin sulfate, acetylglucosamine, glycerophosphorylcholine, glyceroglycosides, hydrolyzed hyaluronic acid, collagen peptides, sitosterol, carnosine, creatine, phytic acid, N-methylserine, 3-methylcyclopentadecanone, saponins, genistein, soy flavone, phytol; and plant extracts having a hyaluronic acid production-promoting effect, such as marjoram, peppermint, apple mint, perilla, lemon, meng Sang, clathrum, bread fruit, papermulberry, paper mulberry, fig, ulva, mallow, pennywort, phellodendron, houttuynia cordata, achillea, almond, hawthorn, linseed, gardenia, nettle, strawberry seed, carambola, passion fruit, sea grape, saffron, camellia, pumpkin, towel gourd, asparagus, gynostemma pentaphylla, kuh-seng, dried orange peel, peony, persimmon, red sage, centella, puer tea, maitake mushroom, water shield, horsetail, pear, chamomile, and the like.
Examples of the intracellular active oxygen scavenger that can be used in combination include ascorbic acid, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and other ascorbyl phosphate salts; ascorbyl fatty acid esters such as ascorbyl monostearate, ascorbyl monopalmitate, ascorbyl dipalmitate, and ascorbyl tetraisopalmitate; ascorbyl ethers such as 3-O-ethyl ascorbate, 2-O-ethyl ascorbate, cetyl ascorbate, glycerin ascorbate, and hexylglycerin ascorbate; ascorbyl glucoside such as ascorbyl-2-glucoside and fatty acid esters thereof; ascorbic acid derivatives such as ascorbyl sulfate and tocopheryl phosphate; retinoids such as retinol, retinol acetate, retinol palmitate, hydrogenated retinol, and the like; vitamin E such as tocopherol, tocopheryl acetate, tocotrienol, etc.; carotenoids such as carotenes, lycopene, astaxanthin, and lutein; polyphenols such as brown algae polyphenols, curcumin, anthocyanin, procyanidine, catechin, ellagic acid, and apple polyphenols; coenzyme Q10, lipoic acid, lactoferrin, sesamin, lignans, chlorogenic acid, rutin; and plant extracts having intracellular active oxygen scavenging effect, such as radix Scutellariae, herba Rosmarini officinalis, fructus Eriobotryae, flos lupuli, flos Rosae Multiflorae, aspalathus linearis, hamamelis virginiana, thyme, radix Gentianae, peony, shell matrix, radix Sanguisorbae, flos Chrysanthemi, radix Dauci Sativae, herba Salvia officinalis (herba Lespedezae Cuneatae), fructus forsythiae, mori fructus, peppermint, pyracantha fortuneana, lemon, olive leaf, hypericum perforatum, grape leaf, angelica keiskei Koidz, catechu, semen Ginkgo, herba Urticae Cannabinae, herba Artemisiae Scopariae, mallow, oolong tea, fructus Rosae Davuricae, herba Rabdosiae Glaucocalycis, mugwort, flos Matricariae Chamomillae, glycyrrhrizae radix, flos Lonicerae, radix Sophorae Flavescentis, herba Erodii Geranii, black tea, herba Potentillae, herba Saponici, herba Centellae, folium Camelliae sinensis, flos Caryophylli, pericarpium Citri Tangerinae, sweet tea, herba Sidae Rhus, ramulus et Gemma Nitidae, fructus Avenae, herba Pogostemonis, herba Menthae, herba Melissae, herba Pogostemonis, folium.
Specific examples of the irritation-reducing agent that can be used in combination include mannitol erythritol, diethylene glycol dimer linoleate oligomer (dimer dilinoleate diethylene glycololigomer ester), malic acid diisostearate, N-acyl-L-glutamic acid, trehalose monofatty acid ester, fatty acid amide amine oxide, alkyl dimethyl amine oxide, phenylethyl glucoside, lauryl glucoside, ferulic acid glucoside, salicin, cedrol, polyethylene glycol, and polypropylene glycol; plant extracts with irritation relieving effects such as red flower, flower cage, peppermint, uncaria gambir, olive, etc.
Specific examples of the wrinkle-improving agent that can be used in combination include isopropyl-oxo-propyl-aminocarbonyl-pyrrolidine-carbonyl-methyl-propyl-aminocarbonyl-benzoyl-amino-acetic acid Na, retinol, nicotinamide, tranexamic acid, and 3-O-ethyl-ascorbic acid. Examples of the blood circulation accelerator include capsaicin, niacin, nicotinamide, tocopheryl nicotinate, tocopherol, tocopheryl acetate, oryzanol, dl-camphor, ginseng extract, ginkgo leaf extract, angelica extract, white birch extract, cinnamon extract, peony extract, saffron extract, wheat germ extract, ginger rhizome extract, capsicum extract, carrot extract, stachys sieboldii extract, mugwort extract, and angelica keiskei extract.
The present invention includes an invention relating to a complex for preparing an emulsified or dissolved composition, which is obtained by removing an organic solvent from a dispersion or solution in which the following components (A1) to (A3) are uniformly dispersed or dissolved in the organic solvent and precipitating the components (A1) to (A3) at the same time.
(A1) Phosphatidylinositol
(A2) Lecithin
(A3) Sterols
A complex is defined herein as a mixture of substances that maintains the chemical properties of each monomer, while exhibiting a physicochemical property as a complex. Examples of such physicochemical properties include changes in the formation of a complex with respect to temperature, and changes in the solubility and dispersibility with respect to a solvent.
The method for producing the composite of the present invention is as follows. First, the above components (A1), (A2) and (A3) are uniformly dispersed or dissolved in an organic solvent. The dispersion or dissolution may be carried out according to a usual method, and examples thereof include stirring, homogenization, and the like. In this case, if heating is performed, the heating can be efficiently performed.
Then, the organic solvent is removed from the organic solvent solution to precipitate phosphatidylinositol, lecithin and sterols at the same time. Examples of the method include a method of distilling the organic solvent solution under heating and/or reduced pressure to remove the organic solvent; a method of spray-drying the above organic solvent solution; and a method in which the organic solvent is frozen instantaneously with liquid nitrogen or the like and then lyophilized. The target complex can be obtained in the form of a semisolid, a solid or a powder by such a method, and is preferably obtained in the form of a powder from the viewpoint of the swelling rate when dispersed in water. Therefore, spray drying and freeze drying are preferably used as the production method, and further, as spray drying, the following apparatus (instantaneous vacuum dryer) is most preferably used: the organic solvent solution is supplied to a tubular heater at a constant speed, heated in the heater to evaporate the organic solvent, a mixture of a solid component and a vapor of the organic solvent is substantially formed, and the mixture is introduced into a vacuum chamber at a high speed to volatilize the organic solvent instantaneously. Patent document 7 describes the details of the present apparatus.
The organic solvent used in the production of the composite of the present invention is not particularly limited as long as it can uniformly dissolve or disperse all the components of the composite, and examples thereof include hydrocarbons such as pentane, hexane, heptane, and cyclohexane; halogenated hydrocarbons such as methylene chloride and chloroform; aromatic hydrocarbons such as benzene and toluene; lower alcohols such as methanol, ethanol, isopropanol, and t-butanol; esters such as methyl acetate and ethyl acetate. These organic solvents may be used alone or in combination of 2 or more. Among these, from the viewpoints of solubility, safety, and the like, hydrocarbons such as pentane, hexane, heptane, cyclohexane, and the like, and lower alcohols such as methanol, ethanol, isopropanol, tert-butanol, and the like are exemplified as preferable solvents.
The amount of the organic solvent used in the production of the composite of the present invention is not particularly limited as long as the entire component to be compounded is dissolved or uniformly dispersed, and the amount to be used may be appropriately changed depending on the solubility of the component to be compounded. In general, the amount of the compound may be 1 to 100 times by weight, preferably 3 to 50 times by weight, based on the total amount of the components to be compounded.
The phosphatidylinositol of component (A1) used in the complex of the present invention is 1 kind of phospholipid which is naturally present in plants such as soybean, rapeseed, sunflower, corn and palm, and is contained in lecithin extracted from these plants. The PI-containing composition can be obtained in a high concentration by fractionation from such lecithin by solvent separation, column purification, or the above-described method using an enzyme, and such PI-containing composition can be used as component (A1) in the complex of the present invention. The high-concentration PI composition produced by the above-described method including the steps (1) to (3) may be preferably used, and as described above, the high-concentration PI-containing composition produced by such a method can be industrially and inexpensively obtained, and is commercially available as Soybrain PI50 (manufactured by unitefoods corporation). Such commercial products can be used in the present invention.
Examples of the lecithin as the component (A2) used in the composite of the present invention include natural lecithins obtained from plants such as soybean, rapeseed, sunflower, peanut, cotton seed, corn, rice, barley and egg yolk, and hydrogenated products thereof. These may be derivatives modified with polyoxyalkylene such as polyethylene glycol. These may be used alone or in combination of 2 or more. Generally, lecithin derived from natural plants contains about 30% by weight of phosphatidylcholine (hereinafter, also referred to as PC), and products having a PC content increased by solvent separation or the like are commercially available. In the present invention, from the viewpoint of improving dispersibility into water, a product having an increased PC content is preferably used, and the PC content in the component (A2) is preferably 50 to 99% by weight, more preferably 70 to 99% by weight. In addition, plant-derived lecithin contains about 10 to 20 wt% PI, and in lecithin with an increased PC content, PI is removed during the separation process, so PI is hardly contained. Therefore, in order to obtain a phospholipid composition having a high PC content and containing PI, it is preferable to mix a composition containing a high concentration of PI with lecithin having an increased PC content. Lecithin obtained from egg yolk naturally contains about 70 wt% of PC (no PI), and can be preferably used as the component (A2), and in view of the natural intention of consumers, lecithin derived from plant sources is preferably used. In addition, from the viewpoint of improving the feel of use when dispersing the complex of the present invention in water, it is preferable to use a mixture of hydrogenated lecithin and non-hydrogenated lecithin as the component (A2). As the mixing ratio of hydrogenated lecithin and non-hydrogenated lecithin, 99:1 to 70:30, more preferably 97:3 to 80:20.
In the present invention, the component (A2) is used for the purpose of assisting the dispersion of the component (A1). The blending ratio of the components (A1) and (A2) used in the present invention is not particularly limited, and is preferably 5 in terms of weight ratio from the viewpoint of sufficiently exhibiting the dispersibility and physiologically active effects of the complex of the present invention in water: 95-50: 50, more preferably 10: 90-30: 70.
specific examples of sterols of component (A3) used in the complex of the present invention include animal-derived sterols such as cholesterol, dihydrocholesterol, lanosterol, dihydrolanosterol, and desmosterol; plant-derived sterols such as stigmasterol, sitosterol, brassicasterol and phytosterols of mixtures of these; sterols derived from microorganisms such as ergosterol; gamma-oryzanol; ursolic acid; glycyrrhetinic acid (Glycyrrhetinic acid); and their esterified products. These sterols may be used alone or in combination of 2 or more. In the present invention, the component (A3) is used to improve the dispersion stability of the resulting emulsified or solubilized composition. Among these sterols, cholesterol, phytosterin and γ -oryzanol are exemplified as preferable examples from the viewpoint of sufficiently exhibiting the effects of the present invention.
The compound of the present invention may further contain an antioxidant substance as component (A4) for the purpose of improving the storage stability of the compound or an emulsified or solubilized composition obtained by dispersing the compound in water. Specific examples of the antioxidant substance include: tocopherol and its derivatives, tocotrienol and its derivatives, gallic acid and its derivatives, ascorbic acid and its derivatives, vitamin A, carotenoids, lipoic acid, coenzyme Q10, panthenol, butylhydroxytoluene, butylhydroxyanisole, etc. Among these, tocopherol and its derivatives, carotenoids, lipoic acid, and coenzyme Q10 are exemplified as preferable examples.
When the composite of the present invention is composed of the components (A1), (A2) and (A3), the total content of the components (A1) and (A2) in the composite is preferably 60 to 99 wt%, the content of the component (A3) is preferably 1 to 40 wt%, the total content of the components (A1) and (A2) is more preferably 70 to 98 wt%, and the content of the component (A3) is preferably 2 to 30 wt%. When the composition further contains the component (A4), the total content of the components (A1) and (A2) in the composition is preferably 40 to 98.99 wt%, the content of the component (A3) is 1 to 40 wt%, the content of the component (A4) is 0.01 to 20 wt%, the total content of the components (A1) and (A2) is more preferably 70 to 97 wt%, the content of the component (A3) is 2 to 20 wt%, and the content of the component (A4) is 1 to 10 wt%.
By using the complex of the present invention thus obtained, phosphatidylinositol which is difficult to disperse in water alone can be easily dispersed in water, and a stable emulsified or solubilized composition can be obtained. The phosphatidylinositol as the component (A1) has excellent physiological activities such as hyaluronic acid production promoting action, intracellular active oxygen scavenging action, whitening action, collagen production promoting action and wrinkle improving action, and the complex of the present invention containing the phosphatidylinositol has excellent physiological activity, but, more surprisingly, the effect is more excellent when used as a complex.
When the compound of the present invention is dispersed in water, the compound may be directly added to water and mixed with stirring, and it is preferable to prepare the compound by a method in which the compound is dispersed in the polyol once, water is added to the resulting polyol dispersion with stirring, or the polyol dispersion is added to water with stirring. The emulsion-soluble composition prepared by such a method exhibits a transparent appearance and further exhibits improved dispersion stability. In the present invention, the appearance of transparent feeling means that the transparent feeling is observed from the back of the liquid when the sample is put in a glass bottle having a diameter of 3.5cm and the glass bottle is viewed from the side.
Therefore, such a polyol dispersion (premix composition) is prepared in advance, and the preparation of the emulsified or solubilized composition becomes easier. Further, when the components of the composite of the present invention are not compounded and are blended separately, they cannot be dispersed in water. On the other hand, when the dispersion is first carried out in the polyol and then carried out in water, the dispersion can be prepared by blending the dispersion, but the compound of the present invention is advantageous in that it requires a longer time for stirring and mixing for uniform dispersion of the polyol and the dispersion stability of the resulting emulsified or solubilized composition is sometimes poor, compared with the case of using the compound of the present invention.
Specific examples of the polyhydric alcohol to disperse the composite of the present invention include dihydric alcohols such as ethylene glycol, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, 2-methyl-1, 3-propanediol, 3-methyl-1, 3-butanediol (isoprene glycol), tetramethylene glycol, isohexylene glycol, octylene glycol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-heptanediol, 1, 2-octanediol, and 1, 2-decanediol; triols such as glycerin, trimethylolpropane, and 1,2, 6-hexanetriol; sugar alcohols such as sorbitol, xylitol, erythritol, maltitol, mannitol, and pentaerythritol; glycerol ethers such as ethyl glycerol, butyl glycerol, hexyl glycerol, and ethylhexyl glycerol; polyhydric alcohol polymers such as diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, diglycerol, triglycerol, tetraglycerol, and polyglycerol. These may be used alone or in combination of 2 or more. Among these, glycerin, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, isohexanediol, 1, 2-pentanediol, and 1, 2-hexanediol are exemplified as preferable examples, and it is particularly preferable that at least 1 selected from the group consisting of isohexanediol, 1, 2-pentanediol, and 1, 2-hexanediol must be contained from the viewpoints of transparency and dispersion stability of the obtained emulsified and solubilized composition.
The cosmetic or external skin preparation containing the complex of the present invention may contain, as necessary, an additive component usually blended in cosmetics, such as an oily base, a surfactant, an alcohol, a humectant, a polymer-thickening-gelling agent, an antioxidant, a preservative, a bactericide, a chelating agent, a pH adjuster-acid-base, an ultraviolet absorber, a whitening agent, a solvent, a exfoliating-dissolving agent, an antipruritic agent, an antiinflammatory agent, an antiperspirant, a cooling agent, an antihistamine, an astringent, a stimulant, a germinal agent-blood circulation accelerator, a reducing agent-oxidizing agent, a polymer powder, a hydroxy acid, vitamins and derivatives thereof, saccharides and derivatives thereof, organic acids, enzymes, nucleic acids, hormones, inorganic powders, fragrances, and pigments, etc., to the extent that the effects of the present invention are not impaired.
The present invention includes an invention relating to a cosmetic or skin external preparation containing the following components (a) to (C) as essential components.
(A) A composition comprising the following components (A1) and (A2),
(A1) Phosphatidylinositol,
(A2) Lecithin;
(B) A polyol;
(C) And (3) water.
The phosphatidylinositol of component (A1) used in the cosmetic or skin external preparation of the present invention is 1 kind of phospholipid which is naturally present in plants such as soybean, rapeseed, sunflower, corn and palm, and is contained in lecithin extracted from these plants. The PI-containing composition can be obtained in a high concentration by fractionation from such lecithin by solvent separation, column purification, or the above-described method using an enzyme, and such PI-containing composition can be used as the component (A1) in the present invention. The high-concentration PI composition produced by the above-described method including the steps (1) to (3) may be preferably used, and as described above, the high-concentration PI-containing composition produced by such a method can be industrially and inexpensively obtained, and is commercially available as Soybrain PI50 (manufactured by unitefoods corporation). Such commercial products can be used in the present invention.
Examples of the lecithin as the component (A2) used in the cosmetic or skin external preparation of the present invention include natural lecithins obtained from plants such as soybean, rapeseed, sunflower, peanut, cottonseed, corn, rice, barley and egg yolk, and hydrogenated products thereof. These may be derivatives modified with polyoxyalkylene such as polyethylene glycol. These may be used alone or in combination of 2 or more.
Generally, lecithin derived from natural plants contains about 30% by weight of phosphatidylcholine, and products having a PC content increased by solvent separation or the like are commercially available. In the present invention, from the viewpoint of improving dispersibility, a product having an increased PC content is preferably used, and the PC content in the component (A2) is preferably 50 to 99% by weight, more preferably 70 to 99% by weight. In addition, the plant-derived lecithin contains about 10 to 20 wt% PI, and the lecithin having an increased PC content is removed during the separation process, so that it contains almost no PI. Therefore, in order to obtain a phospholipid composition having a high PC content and containing PI, it is preferable to mix a composition containing a high concentration of PI with lecithin having an increased PC content. Lecithin obtained from egg yolk naturally contains about 70 wt% of PC (no PI), and can be preferably used as component (A2), and in view of the natural intention of consumers, lecithin derived from plant is preferably used.
In addition, from the viewpoint of improving the feel of use of the cosmetic or dermatological agent of the present invention, it is preferable to use a mixture of hydrogenated lecithin and non-hydrogenated lecithin as the component (A2). As the mixing ratio of hydrogenated lecithin and non-hydrogenated lecithin, 99:1 to 70:30, more preferably 97:3 to 80:20.
in the present invention, the component (A2) is used for the purpose of assisting the dispersion of the component (A1). The blending ratio of the components (A1) and (A2) used in the present invention is not particularly limited, but is preferably 5 in terms of weight ratio from the viewpoint of sufficiently exhibiting dispersibility in water and physiological activity: 95-50: 50, more preferably 10: 90-40: 60.
in the cosmetic or skin external preparation of the present invention, sterols may be further blended as component (A3) in order to improve dispersion stability. Specific examples of the component (A3) include sterols derived from animals such as cholesterol, dihydrocholesterol, lanosterol, dihydrolanosterol, and desmosterol; plant-derived sterols such as stigmasterol, sitosterol, brassicasterol and phytosterols of mixtures of these; sterols derived from microorganisms such as ergosterol; gamma-oryzanol; ursolic acid; glycyrrhetinic acid; and their esterified products. These may be used alone or in combination of 2 or more. Among these, cholesterol, phytosterin and γ -oryzanol are listed as preferred ingredients. The blending amount of the component (A3) is not particularly limited, and the ratio of the total blending amount of the components (A1) and (A2) to the blending amount of (A3) is preferably 200 in terms of weight ratio: 1 to 1:1, more preferably 100: 1-2: 1.
The cosmetic or external preparation of the present invention may further contain an antioxidant substance as component (A4) for the purpose of improving the storage stability of the cosmetic or external preparation. Specific examples of the antioxidant substance include: tocopherol and its derivatives, tocotrienol and its derivatives, gallic acid and its derivatives, ascorbic acid and its derivatives, vitamin A, carotenoids, lipoic acid, coenzyme Q10, panthenol, butylhydroxytoluene, butylhydroxyanisole, etc. Among these, tocopherol and its derivatives, carotenoids, lipoic acid and coenzyme Q10 are exemplified as preferable examples. The blending amount of the component (A4) is not particularly limited, and the ratio of the total blending amount of the components (A1) and (A2) to the blending amount of (A4) is preferably 400 in terms of weight ratio: 1-2: 1, more preferably 200:1 to 3:1.
the above-mentioned compound can be used as the component (a) used in the cosmetic or external skin preparation of the present invention.
The blending amount of the component (a) used in the cosmetic or skin external preparation of the present invention is not particularly limited, but is preferably 0.001 to 5% by weight, more preferably 0.005 to 2% by weight, and even more preferably 0.01 to 1% by weight, from the viewpoints of dispersion stability and transparency of the obtained cosmetic or skin external preparation.
The polyol of the component (B) used in the cosmetic or dermatological external preparation of the present invention is used for the purpose of dispersing the component (A) in water simply and stably. Specific examples of the component (B) include diols such as ethylene glycol, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, 2-methyl-1, 3-propanediol, 3-methyl-1, 3-butanediol (isoprene glycol), tetramethylene glycol, isohexylene glycol, octanediol, 1, 2-pentanediol (pentanediol), 1, 2-hexanediol, 1, 2-heptanediol, 1, 2-octanediol, and 1, 2-decanediol; triols such as glycerin, trimethylolpropane, and 1,2, 6-hexanetriol; sugar alcohols such as sorbitol, xylitol, erythritol, maltitol, mannitol, and pentaerythritol; glycerol ethers such as ethyl glycerol, butyl glycerol, hexyl glycerol, and ethylhexyl glycerol; polyhydric alcohol polymers such as diethylene glycol, triethylene glycol, tetraethylene glycol, polyethylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, diglycerol, triglycerol, tetraglycerol, and polyglycerol. These may be used alone or in combination of 2 or more. Among these, glycerin, propylene glycol, 1, 3-propanediol, 1, 2-butanediol, 1, 3-butanediol, isohexanediol, 1, 2-pentanediol and 1, 2-hexanediol are exemplified as preferable examples from the viewpoint of dispersibility of the component (A) in water. In addition, from the viewpoints of transparency and dispersion stability of the obtained cosmetic or skin external preparation, it is particularly preferable that at least 1 selected from the group consisting of isohexanediol, 1, 2-pentanediol and 1, 2-hexanediol must be contained. By containing such an essential polyol, a cosmetic or skin external preparation excellent not only in initial dispersibility but also in transparency and dispersion stability can be obtained. In order to obtain a cosmetic or skin external preparation having transparency in appearance, it is desirable that such an essential polyol is contained in the component (B) at a concentration of 20% by weight or more, preferably 25% by weight or more, and most preferably 28% by weight or more.
The blending ratio of the components (a) and (B) used in the cosmetic or skin external preparation of the present invention is preferably 1 in terms of weight ratio from the viewpoint of obtaining a cosmetic or skin external preparation excellent in transparency and dispersion stability: 5 to 1:200, more preferably set to 1:10 to 1:150.
the water as the component (C) used in the cosmetic or external skin preparation of the present invention is not particularly limited as long as it can be used in usual cosmetics, and purified water, ion-exchanged water, distilled water, natural water, deep sea water, hydrogen-rich water, and the like can be used. The water may be water having its pH adjusted by an acid, a base, a buffer, a chelating agent, or the like, or water to which a preservative is added.
In the cosmetic or skin external preparation of the present invention, a nonionic surfactant may be further blended as component (D) in order to improve transparency and dispersion stability of the obtained cosmetic or skin external preparation. Specific examples of the component (D) include fatty acid glycerides, polyglycerin fatty acid esters, sucrose fatty acid esters, mannitol erythritol esters, polyoxyethylene fatty acid glycerides, polyoxyethylene fatty acid sorbitan esters, polyoxyethylene fatty acid esters, and polyoxyethylene alkyl ethers. These may be used alone or in combination of 2 or more. Among these, fatty acid glycerides, polyglycerol fatty acid esters, sucrose fatty acid esters, mannitol erythritol esters, polyoxyethylene fatty acid sorbitan esters, and polyoxyethylene alkyl ethers are cited as preferable examples.
More specific examples of the fatty acid glyceride of the component (D) include monoesters of fatty acids having 8 to 22 carbon atoms and glycerin. Among them, preferable examples include caprylic acid glyceride, capric acid glyceride, lauric acid glyceride, myristic acid glyceride, palmitic acid glyceride, stearic acid glyceride, oleic acid glyceride, isostearic acid glyceride, behenic acid glyceride, and the like, and most preferable examples are caprylic acid glyceride, capric acid glyceride, and lauric acid glyceride.
More specific examples of the polyglycerin fatty acid ester of the component (D) include monoesters, diesters, triesters and tetraesters of fatty acids having 8 to 22 carbon atoms with polyglycerins preferably having a polymerization degree of 2 to 20, more preferably having a polymerization degree of 6 to 12. Among them, preferable examples include: caprylic acid polyglycerin ester, capric acid polyglycerin ester, lauric acid polyglycerin ester, myristic acid polyglycerin ester, palmitic acid polyglycerin ester, stearic acid polyglycerin ester, oleic acid polyglycerin ester, isostearic acid polyglycerin ester, behenic acid polyglycerin ester, dicaprylic acid polyglycerin ester, dicaprac acid polyglycerin ester, dilaurate polyglycerin ester, dimyristate polyglycerin ester, distearic acid polyglycerin ester, dioleic acid polyglycerin ester, diisostearic acid polyglycerin ester, behenic acid polyglycerin ester, tricaprylin, trioleate polyglycerin ester, triisostearic acid polyglycerin ester, and tricaprin polyglycerin ester, particularly preferably caprylic acid polyglycerin ester, capric acid polyglycerin ester, lauric acid polyglycerin ester, dicaprac acid polyglycerin ester, and dilaurate polyglycerin ester.
More specific examples of the sucrose fatty acid ester of the component (D) include monoesters, diesters, triesters and tetraesters of fatty acids having 8 to 22 carbon atoms with sucrose. Among them, as preferable examples, there can be cited sucrose laurate, sucrose myristate, sucrose palmitate, sucrose stearate, sucrose oleate, sucrose behenate, sucrose erucate, sucrose dilaurate, sucrose dimyristate, sucrose dipalmitate, sucrose distearate, sucrose dioleate, sucrose dibehenate, sucrose distearate, sucrose trilaurate, sucrose trimyristate, sucrose tripalmitate, sucrose tristearate, sucrose trioleate, sucrose trilhenate, sucrose trilerucate, and the like, with preference given to sucrose laurate, sucrose myristate, sucrose palmitate, sucrose dilaurate, sucrose dimyristate, and sucrose dipalmitate.
The mannitol erythritol lipid used as the component (D) is a generic term for compounds represented by the following general formula (1), and more specific examples thereof include: r of the general formula (1) 1 And R is 2 Is acyl, R 3 And R is 4 Is acetyl, R 5 MEL-a of a compound that is hydrogen R of the general formula (1) 1 And R is 2 Is acyl, R 3 Is hydrogen, R 4 Is acetyl, R 5 MEL-B of a compound that is hydrogen; r of the general formula (1) 1 And R is 2 Is acyl, R 3 Is acetyl, R 4 Is hydrogen, R 5 MEL-C of a compound that is hydrogen; r of the general formula (1) 1 And R is 2 Is acyl, R 3 And R is 4 Is hydrogen, R 5 MEL-D, a compound that is hydrogen. Among these, MEL-B or MEL-C is preferred, and MEL-B is most preferred.
(wherein R is 1 、R 2 Represents hydrogen or an aliphatic acyl group having 2 to 24 carbon atoms (but not simultaneously hydrogen). In addition, R 3 、R 4 Represents hydrogen or acetyl, R 5 Represents hydrogen or an aliphatic acyl group having 2 to 24 carbon atoms. )
More specific examples of the polyoxyethylene fatty acid glyceride of the component (D) include monoesters, diesters, and triesters of polyoxyethylene glycerol adducts having an addition mole number of 4 to 200, more preferably 8 to 100, to polyoxyethylene (E.O) and fatty acids having 8 to 22 carbon atoms. Among them, polyoxyethylene caprylate, polyoxyethylene caprate, polyoxyethylene laurate, polyoxyethylene myristate, polyoxyethylene palmitate, polyoxyethylene stearate, polyoxyethylene oleate, polyoxyethylene isostearate, polyoxyethylene dicaprylate, polyoxyethylene dicaprate, polyoxyethylene dilaurate, polyoxyethylene dimyristate, polyoxyethylene dipalmitate, polyoxyethylene distearate, polyoxyethylene dioleate, polyoxyethylene diisostearate, polyoxyethylene trioctanoate, polyoxyethylene tricaprate, polyoxyethylene trilaurate, polyoxyethylene trimyristate, polyoxyethylene tripalmitate, polyoxyethylene tristearate, polyoxyethylene trioleate, polyoxyethylene triisostearate and the like are particularly preferable, and polyoxyethylene caprylate, polyoxyethylene caprate, polyoxyethylene laurate and polyoxyethylene laurate are most preferable.
More specific examples of the polyoxyethylene fatty acid sorbitan ester of the component (D) include monoesters, diesters, and triesters of sorbitan polyoxyethylene adducts having an addition mole number of preferably 4 to 200, more preferably 8 to 100, with fatty acids having 8 to 22 carbon atoms, and the like, to polyoxyethylene (E.O). Among them, polyoxyethylene caprylate sorbitan ester, polyoxyethylene caprate sorbitan ester, polyoxyethylene laurate sorbitan ester, polyoxyethylene myristate sorbitan ester, polyoxyethylene palmitate sorbitan ester, polyoxyethylene stearate sorbitan ester, polyoxyethylene oleate sorbitan ester, polyoxyethylene isostearate sorbitan ester, polyoxyethylene dioctanoate sorbitan ester, polyoxyethylene dicaprate sorbitan ester, polyoxyethylene dilaurate sorbitan ester, polyoxyethylene dimyristate sorbitan ester, polyoxyethylene dipalmitate sorbitan ester, polyoxyethylene distearate sorbitan ester, polyoxyethylene dioleate sorbitan ester, polyoxyethylene diisostearate sorbitan ester, polyoxyethylene trioctanoate sorbitan ester, polyoxyethylene tridentate sorbitan ester, polyoxyethylene trilaurate sorbitan ester, polyoxyethylene trimyristate sorbitan ester, polyoxyethylene tripalmitate sorbitan ester, polyoxyethylene tristearate sorbitan ester, polyoxyethylene trioleate sorbitan ester, and polyoxyethylene tristearate sorbitan ester and the like are particularly preferable, most preferred are polyoxyethylene sorbitan octoate, polyoxyethylene sorbitan decanoate, polyoxyethylene sorbitan laurate, polyoxyethylene sorbitan oleate, and polyoxyethylene sorbitan isostearate.
More specific examples of the polyoxyethylene fatty acid ester of the component (D) include monoesters and diesters of polyoxyethylene (E.O) having preferably 4 to 200, more preferably 8 to 100, and fatty acids having 8 to 22 carbon atoms, in terms of the molar number of addition to the polyoxyethylene. Among them, polyoxyethylene caprylate, polyoxyethylene caprate, polyoxyethylene laurate, polyoxyethylene myristate, polyoxyethylene palmitate, polyoxyethylene stearate, polyoxyethylene oleate, polyoxyethylene isostearate, polyoxyethylene behenate, polyoxyethylene dicaprylate, polyoxyethylene dicaprate, polyoxyethylene dilaurate, polyoxyethylene dimyristate, polyoxyethylene dipalmitate, polyoxyethylene distearate, polyoxyethylene dioleate, polyoxyethylene diisostearate, polyoxyethylene behenate and the like are particularly preferable, and polyoxyethylene caprylate, polyoxyethylene caprate, and polyoxyethylene laurate are most preferable.
More specific examples of the polyoxyethylene alkyl ether of the component (D) include those obtained by adding polyoxyethylene (E.O) to a lipophilic compound having a hydroxyl group, such as an alcohol having 8 to 32 carbon atoms or castor oil, preferably 4 to 200 moles, more preferably 8 to 100 moles. Among them, polyoxyethylene decyl ether, polyoxyethylene octyl ether, polyoxyethylene lauryl ether, polyoxyethylene myristyl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene isostearyl ether, polyoxyethylene behenyl ether, polyoxyethylene cholesterol ether, polyoxyethylene phytosterol ether, and hydrogenated castor oil polyoxyethylene ether are particularly preferable, and polyoxyethylene decyl ether, polyoxyethylene octyl ether, polyoxyethylene lauryl ether, polyoxyethylene cholesterol ether, polyoxyethylene phytosterol ether, and hydrogenated castor oil polyoxyethylene ether are most preferable.
The blending amount of the component (D) used in the cosmetic or skin external preparation of the present invention is preferably 1 in terms of the blending ratio of the components (a) and (D) from the viewpoint of obtaining a cosmetic or skin external preparation excellent in transparency and dispersion stability: 0.1 to 1:10, more preferably 1:0.2 to 1:5.
in the cosmetic or skin external preparation of the present invention, the appearance of transparency means that the transparent feeling of the back of the liquid can be seen through the liquid when the sample is put in a glass bottle having a diameter of 3.5cm and viewed from the side. When turbidity was measured by a spectrophotometer, a sample was placed in a sample cell having a thickness of 1cm, and the transmittance was 60% or more when measured at a wavelength of 600 nm.
As a method for producing the cosmetic or skin external preparation of the present invention, first, the following methods are listed: the components (A) and (B) or the components (A), (B) and (D) are heated and mixed with stirring to prepare a polyol dispersion, and water is added to the obtained polyol dispersion with stirring. In this case, the polyol dispersion may be added to water while stirring. As described above, phosphatidylinositol is difficult to disperse in water when used alone, but by such a method, phosphatidylinositol can be dispersed in water easily and stably, and a cosmetic or skin external preparation excellent in transparency and dispersion stability can be obtained.
The phosphatidylinositol as the component (A1) of the present invention has excellent physiological activities such as hyaluronic acid production promoting action, intracellular active oxygen scavenging action, whitening action, collagen production promoting action and wrinkle improving action, and the cosmetic or skin external preparation of the present invention containing the PI also has excellent physiological activity.
The cosmetic or external skin preparation of the present invention may contain, if necessary, an additive component ordinarily incorporated in cosmetics, for example, at least 1 selected from the group consisting of oily bases, surfactants, alcohols, moisturizers, polymer-thickening-gelling agents, antioxidants, preservatives, bactericides, chelating agents, pH adjusting agents-acid-bases, ultraviolet absorbers, whitening agents, solvents, exfoliating-dissolving agents, antipruritics, anti-inflammatory agents, antiperspirant agents, cooling agents, antihistamines, astringents, stimulators, hair-growing agents-blood circulation promoters, reducing agents-oxidizing agents, polymer powders, hydroxy acids, vitamins and derivatives thereof, saccharides and derivatives thereof, organic acids, enzymes, nucleic acids, hormones, inorganic powders, perfumes, pigments, and the like, to the extent that the effects of the present invention are not impaired.
While the embodiments of the present invention have been described above, the present invention is not limited to these examples, and can be implemented in various ways without departing from the scope of the present invention.
Examples
Hereinafter, embodiments of the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.
Evaluation of physiological Activity of phosphatidylinositol
The whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, intracellular active oxygen scavenging effect, irritation relieving effect, and wrinkle improving effect were confirmed on phosphatidylinositol by the following experiments. The phosphatidylinositol used in this test was a high-concentration PI composition (Soybrain PI50 from unitefoods) obtained by the above-described method including steps (1) to (3) and phosphatidylinositol obtained by separating only PI from the resultant product by column chromatography (hereinafter referred to as high-purity PI). The composition of each component contained in the Soybrain PI50 used this time was confirmed as the composition of table 1 by separation by column chromatography and analysis by analytical instruments such as HPLC, NMR and IR.
TABLE 1
Weight percent
Composition of the components | Composition of the composition |
Phosphatidylinositol (PI) | 60 |
Phosphatidylethanolamine (PE) | 5 |
Phosphatidic Acid (PA) | 1 |
Sterol glucosides | 6 |
Triglycerides (Triglycerides) | 2 |
Unidentified | 26 |
< melanogenesis inhibitory Effect >
B16F10 mouse melanoma cells were cultured in the medium to which each test sample was added at the concentrations described in table 2 for 72 hours. After completion of the addition culture, a 2N aqueous sodium hydroxide solution containing 10% dimethyl sulfoxide was added to the recovered cells, and the mixture was heated to 60℃to form a cell lysate. The absorbance at 450nm was measured for the obtained cell lysate, and the amount of melanin in the pigment cells was measured. Further, protein concentration of the cell lysate was quantified using Protein Assay Dye Reagent Concentrate (BIO-RAD) based on bovine serum albumin (Thermo scientific Co.) to calculate the amount of melanin per unit protein mass. As a control, the amount of melanin in the medium to which the test sample was not added was similarly measured. The results are shown in Table 2 as relative values when the amount of melanin in the control is 100%.
TABLE 2
Melanogenesis inhibitory effect
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: sample obtained by separating only PI from Soybrain PI50
< evaluation of promotion of collagen production >)
After normal human dermal fibroblasts were cultured in a medium to which each test sample was added at the concentrations shown in Table 3 for 72 hours, the amount of type I collagen in the supernatant of the medium was quantified by ELISA. As a control, the amount of type I collagen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 3 as relative values when the amount of type I collagen of the control was set to 100%.
TABLE 3
Evaluation of promotion of type I collagen production
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
< evaluation of promotion of hyaluronic acid production >
After culturing normal human epidermal cells in a medium to which each test sample was added at the concentrations shown in table 4 for 72 hours, the amount of hyaluronic acid in the culture supernatant was quantified by ELISA. As a control, the amount of hyaluronic acid in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 4 as relative values when the amount of hyaluronic acid of the control was set to 100%.
TABLE 4
Evaluation of promotion of hyaluronic acid production
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: sample obtained by separating only PI from Soybrain PI50
< evaluation of intracellular active oxygen clearance >
After culturing normal human epidermal cells in a medium to which each test sample was added at the concentrations shown in Table 5 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and then exposed to 2' -7' -dichlorofluorescein (Dichlorofluorescin) (SIGMA) containing fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes. Then, the sample was exposed to HBSS (-) containing 500. Mu.M hydrogen peroxide as active oxygen, and the amount of intracellular active oxygen after 1 hour was quantified by a fluorescence microplate reader (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 5 as relative values when the amount of active oxygen in the cells of the control was set to 100%.
TABLE 5
Evaluation of intracellular active oxygen elimination
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: sample obtained by separating only PI from Soybrain PI50
< evaluation of inhibition of SLS-inducible intracellular Activity
After normal human epidermal cells were cultured in a medium containing 10. Mu.g/mL of sodium dodecyl sulfate (SLS) and the concentrations shown in Table 6 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and exposed to HBSS (-) containing 2' -7' -dichlorofluorescein (SIGMA Co.) as a fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes, and the cells were allowed to take in the fluorescent probe, and the amount of active oxygen in the cells was quantified by a fluorescent enzyme-labeled instrument (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample (SLS alone) was not added was similarly quantified. The results are shown in Table 6 as relative values when the amount of active oxygen in the cells of the control was set to 100%.
TABLE 6
Evaluation of inhibition of SLS-inducible intracellular reactive oxygen species
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
< evaluation of inhibition of cytotoxicity caused by SLS >
After normal human epidermal cells were cultured in a medium containing 25. Mu.g/mL of sodium dodecyl sulfate (SLS) and the concentrations shown in Table 7 for 24 hours, they were stained with WST-8 (the same core chemical institute) and the cell viability was measured by absorbance (450 nm). The results are shown in Table 7 as relative values when the cell viability of the control (no SLS added and test sample) was 100%.
TABLE 7
Evaluation of inhibition of cytotoxicity by SLS
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: sample obtained by separating only PI from Soybrain PI50
From the results shown in tables 2 to 5, phosphatidylinositol has excellent whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect and intracellular active oxygen scavenging effect. The high-concentration PI composition of the present invention obtained by the method comprising the steps (1) to (3) gives a more excellent effect than the high-purity PI. In addition, it is suggested that exposure of SLS causes an increase in intracellular active oxygen through interaction with cell membranes, and is associated with induction of skin roughness. In addition, it is considered that the decrease in cell viability (cytotoxicity) due to SLS exposure is associated with stimulation. From the results shown in Table 6, it was found that phosphatidylinositol inhibited the increase in intracellular active oxygen caused by SLS, and from the results shown in Table 7, it was assumed that phosphatidylinositol had a stimulating effect of alleviating cytotoxicity by SLS.
< evaluation of wrinkle improvement >
The wrinkle-improving action was confirmed by following the method "instruction manual for evaluation of anti-wrinkle articles for obtaining new efficacy" formulated by the japan cosmetic society. 18 healthy adult females (35-58 years old and average 46.3 years old) were treated with the phosphatidylinositol-containing lotion described in Table 8 2 times in the morning and evening of 1 day on one half of the face, and the other half was not applied. Photographs of the outer corners of the eyes were taken on the first day (week 0), week 2 and week 4 of the test, and the wrinkle grade was judged from the obtained images by an expert skilled in evaluating wrinkles (score 0: no wrinkles; score 1: confirming a small number of insignificant shallow wrinkles; score 2: confirming a small number of significant shallow wrinkles; score 3: confirming significant shallow wrinkles). The results are shown in FIG. 1 as the change in wrinkle level.
TABLE 8
Weight percent
Amount of blending | |
The composite of example 3 | 0.2 |
Glycerol | 2 |
1, 2-pentanediol | 3 |
Phenoxyethanol | 0.2 |
Purified water | 94.6 |
From the results of fig. 1, the wrinkle grade did not change significantly with respect to the non-coated portions, and the wrinkle grade was significantly reduced at the portions to which the phosphatidylinositol-containing lotion was applied, and it was found that phosphatidylinositol had an excellent wrinkle-improving effect.
Evaluation of the inventive complexes
< manufacturing of composite >
The components (total 10 g) of the complex of the present invention were dissolved in 80g of t-butanol with the composition shown in Table 9, and then frozen instantaneously with liquid nitrogen, and lyophilized with a lyophilization apparatus (manufactured by Tokyo physical and chemical instruments, model FDU-2200). The pressure was set to 10Pa or less, and the cold trap temperature was set to-80 ℃. The complexes thus obtained were homogeneous pale yellow powders. In addition, as a comparison, a composite of the composition of table 10 was also prepared.
Preparation and evaluation of aqueous dispersion
Using the above-obtained composite, an aqueous dispersion was prepared with the composition shown in table 11. The initial dispersibility, transparency and dispersion stability of the obtained aqueous dispersion were evaluated by the following methods, and the results are shown in the following tables 9 and 10.
< initial dispersibility >)
The dispersion state immediately after the preparation of the aqueous dispersion was visually observed, and the initial dispersibility was evaluated based on the following evaluation criteria.
Uniform dispersion
X. Do not uniformly disperse
Transparency >
The obtained aqueous dispersion was placed in a glass bottle having a diameter of 3.5cm, and the appearance was visually observed from the side, and the transparency was evaluated based on the following evaluation criteria.
Back of liquid visible through liquid
Delta. The back of the liquid is slightly visible through the liquid
Back of the body where no liquid can be seen through the body
< dispersion stability >)
The resulting aqueous dispersion was subjected to a storage stability test at 50℃for 1 month, and the dispersion stability was evaluated on the basis of the following evaluation.
Even after storage
Delta. After storage, also dispersed substantially homogeneously
After storage, the polymer was not uniformly dispersed or precipitated
TABLE 9
Weight percent
/>
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 10
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 11
Weight percent
The preparation method comprises the following steps: no.1 and No.2 were previously stirred and mixed at 80℃to prepare a mixture (part A). No.3 and No.4 were uniformly dissolved at 80 ℃. Part A was added to part B with stirring, and the mixture was stirred with a homogenizer (75 ℃ C., 5000rpm,15 minutes) and cooled.
From the results of table 9, the aqueous dispersion prepared using the compound of the present invention was excellent in initial dispersibility, transparency and dispersion stability. Further, as a result of comparing the use feeling with the aqueous dispersion prepared with the compound of example 1 and example 2, the compound of example 2 in which the non-hydrogenated lecithin was blended was excellent in use feeling such as skin affinity feeling (top-binding) and penetrating feeling. In addition, the compound of example 2 and example 3 showed little change in hue and taste when stored at 50 ℃ for 2 weeks, as a result of comparison of the appearance. On the other hand, according to the results of table 10, the weight ratio of components (A1) and (A2) was 59:41, the compound of comparative example 1 and the compound of comparative example 2 having a blending amount of component (A3) of more than 40% by weight failed to produce a satisfactory aqueous dispersion, and the compound of comparative example 3 containing no component (A3) in the compound was excellent in initial dispersibility and transparency, but insufficient in dispersion stability. In addition, the compound of comparative example 4 having a low PC content in the component (A2) can be dispersed in an initial stage, but the transparency and dispersion stability are poor, and it is considered that the PC content in the component (A2) greatly affects the water dispersibility of the compound.
Preparation and evaluation of aqueous dispersion 2 >
Aqueous dispersions using the compounds of the present invention were prepared with the compositions shown in Table 12. The transmittance (sample cell thickness 1cm, wavelength 600 nm) of the obtained aqueous dispersion was measured as an index of transparency, and the results are shown in Table 12.
TABLE 12
Weight percent
The preparation method comprises the following steps: no.1 and No.2 were previously stirred and mixed at 80℃to prepare a premix composition. The obtained premix composition was added to the aqueous solutions of No.3 and No.4 dissolved at 80℃with stirring, stirred with a homogenizer (75℃5000rpm,15 minutes), and cooled.
From the results shown in Table 12, it was found that when the compound of the present invention was dispersed in water, the transparency of the dispersion liquid was improved by using 1, 2-pentanediol, 1, 2-hexanediol, and isohexanediol as the polyhydric alcohols. In addition, by using these, an aqueous dispersion having high transparency can be obtained even if another polyol is used.
The whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect, and intracellular active oxygen scavenging effect of the complex of the present invention were confirmed by the following experiments.
< melanogenesis inhibitory Effect >
B16F10 mouse melanoma cells were cultured in the medium to which each test sample was added at the concentrations described in table 13 for 72 hours. After completion of the addition culture, a 2N aqueous sodium hydroxide solution containing 10% dimethyl sulfoxide was added to the recovered cells, and the mixture was heated to 60℃to form a cell lysate. The absorbance at 450nm was measured for the obtained cell lysate, and the amount of melanin in the pigment cells was measured. Further, protein concentration of the cell lysate was quantified using Protein Assay Dye Reagent Concentrate (BIO-RAD) based on bovine serum albumin (Thermo scientific Co.) to calculate the amount of melanin per unit protein mass. As a control, the amount of melanin in the medium to which the test sample was not added was similarly measured. The results are shown in Table 13 as relative values when the amount of melanin in the control was 100%.
TABLE 13
Melanogenesis inhibitory effect
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: composite of composition after component (A1) was removed from example 2
< evaluation of promotion of collagen production >)
After normal human dermal fibroblasts were cultured in the medium to which each test sample was added at the concentrations shown in Table 14 for 72 hours, the amount of type I collagen in the supernatant of the medium was quantified by ELISA. As a control, the amount of type I collagen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 14 as relative values when the amount of type I collagen of the control was set to 100%.
TABLE 14
Evaluation of promotion of type I collagen production
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: composite of composition after component (A1) was removed from example 2
< evaluation of promotion of hyaluronic acid production >
After culturing normal human epidermal cells in the medium to which each test sample was added at the concentrations shown in table 15 for 72 hours, the amount of hyaluronic acid in the supernatant of the medium was quantified by ELISA. As a control, the amount of hyaluronic acid in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 15 as relative values when the amount of hyaluronic acid of the control was 100%.
TABLE 15
Evaluation of promotion of hyaluronic acid production
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: composite of composition after component (A1) was removed from example 2
< evaluation of intracellular active oxygen clearance >
After culturing normal human epidermal cells in a medium to which each test sample was added at the concentrations shown in Table 16 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and exposed to HBSS (-) containing 2' -7' -dichlorofluorescein (SIGMA Co.) as a fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes to allow the cells to take in the fluorescent probe. Then, the sample was exposed to HBSS (-) containing 500. Mu.M hydrogen peroxide as active oxygen, and the amount of intracellular active oxygen after 1 hour was quantified by a fluorescence microplate reader (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 16 as relative values when the amount of active oxygen in the cells of the control was set to 100%.
TABLE 16
Evaluation of intracellular active oxygen elimination
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: composite of composition after component (A1) was removed from example 2
< evaluation of inhibition of SLS-inducible intracellular Activity
After normal human epidermal cells were cultured in a medium containing 10. Mu.g/mL of sodium dodecyl sulfate (SLS) and the concentrations shown in Table 17 for 24 hours, the cells were washed with Hank's balanced salt solution (-) (HBSS (-)), and exposed to HBSS (-) containing 2' -7' -dichlorofluorescein (SIGMA Co.) as a fluorescent probe for detecting active oxygen at a concentration of 20. Mu.M for 45 minutes, and the cells were allowed to take in the fluorescent probe, and the amount of active oxygen in the cells was quantified by a fluorescent enzyme-labeled instrument (EX/EM 485/535 nm). As a control, the amount of intracellular active oxygen in the medium to which the test sample was not added was similarly quantified. The results are shown in Table 17 as relative values when the amount of active oxygen in the cells of the control was set to 100%.
TABLE 17
Inhibition of SLS-induced intracellular reactive oxygen species
* : the PI concentration in the medium is shown in brackets
**:Soybrain PI50
* **: composite of composition after component (A1) was removed from example 2
From the results in tables 13 to 17, it was found that the complex of the present invention has excellent whitening effect, collagen production promoting effect, hyaluronic acid production promoting effect and intracellular active oxygen scavenging effect. The compound of the present invention is excellent in effect not only as compared with the case where the compound is not added, but also as compared with the case where the PI composition is used alone at a high concentration.
Evaluation of cosmetic or skin external preparation containing Components (A) to (C)
Lotions containing the components (a) to (C) of the present invention in the compositions shown in tables 18 to 22 were prepared by the following methods. The obtained lotions were evaluated for initial dispersibility, transparency and dispersion stability by the following methods, and the results are collectively shown in the lower column of each table.
< preparation method >)
The components (A) and (B) were previously mixed at 80℃with stirring to prepare a polyol dispersion. The obtained polyol dispersion was added to an aqueous solution of methylparaben and component (C) dissolved at 80℃in advance with stirring, and the mixture was stirred with a homogenizer (75℃at 5000rpm for 15 minutes) and cooled.
< initial dispersibility >)
The dispersion state immediately after the preparation of the obtained toning lotion was visually observed, and the initial dispersibility was evaluated based on the following evaluation criteria.
Uniform dispersion
X. Do not uniformly disperse
Transparency >
The transmittance of the cosmetic water (sample cell thickness 1cm, wavelength 600 nm) was measured using a spectrophotometer. The lotion was placed in a glass bottle having a diameter of 3.5cm, and the appearance was visually observed from the side, and the transparency was evaluated on the basis of the following evaluation.
Back of liquid visible through liquid
Delta. The back of the liquid is slightly visible through the liquid
Back of the body where no liquid can be seen through the body
< dispersion stability >)
The obtained toner was subjected to a storage stability test at 50℃for 1 month, and the dispersion stability was evaluated according to the following evaluation criteria.
Even after storage
Delta. After storage, also dispersed substantially homogeneously
After storage, the polymer was not uniformly dispersed or precipitated
TABLE 18
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 19
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 20
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 21
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 22
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
From the results in tables 18 to 20, it is clear that the component (A) can be easily and stably dispersed in water using the component (B). In particular, when 1, 2-pentanediol, 1, 2-hexanediol, or isohexanediol (an essential polyol) was used as the component (B), the transparency and dispersion stability were very excellent (examples 17 to 19). It is also clear that when the essential polyol is used alone, a water cosmetic excellent in transparency and dispersion stability can be obtained, and when the essential polyol is used in combination with other polyols poor in transparency or dispersion stability, a water cosmetic excellent in transparency and dispersion stability can be obtained (examples 23 to 27). In order to obtain a water lotion excellent in transparency, these essential polyols may be contained in the component (B) in an amount of 25 wt% or more (examples 28 to 30).
From the results in Table 21, it was found that when the ratio of component (A1) in component (A) was high, the dispersion was not possible in the initial stage (comparative example 6). When the ratio of the component (B) to the component (a) is low, the dispersion cannot be made in the initial stage (comparative example 7). From the results shown in Table 22, it was found that the component (A2) has high PC content and is excellent in transparency and dispersion stability (examples 35 to 37).
Evaluation of cosmetic or skin external preparation containing Components (A) to (D)
The lotions containing the components (a) to (C) and the component (D) of the present invention in the compositions of tables 23 to 25 were prepared by the following methods. The obtained lotions were evaluated for initial dispersibility, transparency and dispersion stability in the same manner as described above, and the results are also shown in the lower column of each table.
TABLE 23
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 24
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
TABLE 25
Weight percent
*1: soybrain PI50 manufactured by Unitecfoos Inc
From the results in tables 23 to 25, it is clear that the lotions of examples were excellent in transparency and dispersion stability as compared with lotions (comparative examples 8 and 9) containing no component (B) or (D). When the ratio of the component (A1) in the component (a) is high, the dispersion cannot be performed in the initial stage (comparative example 10), and when the PC content in the component (A2) is high, the transparency and dispersion stability are excellent (examples 50 and 52).
The following cosmetics were prepared using the compound of the present invention. The obtained cosmetic has excellent moisture retention and penetration feeling, and can prevent fine wrinkles and rough skin, and make skin look plump and bright.
Example 53 moisturizing lotion
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm), to prepare a nanovesicle (nanovesicle) solution. Then, after cooling, the pre-cooled C part was added to form a uniform solution.
Example 54 moisturizing lotion
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B while stirring with a homomixer (7000 rpm), to prepare a nanovesicle solution. Then, the mixture was dispersed by using a high-pressure emulsifying machine (Microfluidizer, manufactured by MIZUHO Industrial Co., ltd.). After cooling, the pre-cooled C part was added to form a uniform solution.
Example 55 moisturizing lotion
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B while stirring with a homomixer (7000 rpm), to prepare a nanovesicle solution. Then, after cooling, the pre-cooled C part was added to form a uniform solution.
Example 56 moisturizing lotion
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B while stirring with a stirring paddle (500 rpm), to prepare a nanovesicle solution. Then, after cooling, the pre-cooled C part was added to form a uniform solution.
Example 57 whitening lotion
/>
(preparation method)
Mixing part B to prepare a viscous liquid. The portions A and C were heated to 70℃respectively, and the portion A was added to the portion C while stirring with a homomixer (7000 rpm), to prepare a nanovesicle solution. Then, after cooling, the pre-mixed part B was added to form a uniform solution.
Example 58 gel toner
/>
(preparation method)
Part a was heated to about 70 ℃ to uniformly disperse it. Mix part C and stir thoroughly and heat to about 70 ℃ after mixing. The part B was stirred with a stirring paddle to prepare a mixed solution. Part C was added to part A, stirred at about 70℃using a homomixer, cooled to about 40℃and the mixture of part B was added.
EXAMPLE 59 transparent gel
/>
(preparation method)
Stirring the part A by using a stirring paddle to prepare a nano vesicle solution. Mixing the components C to obtain viscous liquid. Mixing part B to form a uniform solution. Part A and part B were added to part C and mixed well.
Example 60 Hair-growing agent
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B while stirring with a homomixer (7000 rpm), to prepare a nanovesicle solution. Then, after cooling, the pre-cooled C part was added to form a uniform solution.
Example 61 two phase separated skin Care solution
/>
(preparation method)
Part a was heated to about 70 ℃ to allow uniform dissolution. Stirring part B to obtain viscous liquid. Parts A and B were added at about 50℃and stirred, and allowed to cool.
Example 62 whitening emulsion
/>
(preparation method)
The portions A and E were heated to about 70℃respectively, and dissolved uniformly. Stirring part B to obtain viscous liquid. Part C was heated to about 70℃to disperse it uniformly. After part A was added while stirring part C with a homogeneous disperser, part E was added while stirring. The portions D and B were added at about 50℃and stirred to be dissolved uniformly.
Example 63 emulsion
/>
(preparation method)
Mixing part A, part B and part D, and heating to about 70deg.C to uniformly dissolve and disperse. Mixing the components C, and stirring to obtain liposome solution. The emulsion was carried out by adding part D to part A while stirring with a homogeneous disperser and adding part B. After cooling, part C was added at about 50 ℃ and stirred, and cooled to about 40 ℃.
Example 64 skin Care cream
/>
(preparation method)
Mixing the part A and the part C respectively, and heating to about 70 ℃ to uniformly dissolve and disperse. Mixing part B, stirring to obtain viscous liquid. The emulsion was obtained by adding part A to part C while stirring with a homomixer. Cooling was performed, part B was added at about 50 ℃, stirred, and cooled to about 40 ℃.
Example 65 skin Care cream
/>
(preparation method)
Mixing part A, part B and part E, and heating to 70deg.C to make it dissolve and disperse uniformly. Mixing the components D, and stirring to obtain viscous liquid. Heating part C to about 70deg.C, mixing, and making into liposome. The part A was stirred with a homogeneous disperser, part B was added, and part E was added to emulsify the mixture. Cooling was performed, parts C and D were added at about 50 ℃ and stirred, cooling to about 40 ℃.
Example 66 skin Care cream
/>
/>
/>
(preparation method)
Mix part a and heat to about 70 ℃ to dissolve. Mixing part B, and stirring to obtain viscous liquid. Mixing part C, heating to about 70deg.C, and dispersing uniformly. Mixing part D, heating to about 70 ℃ to dissolve. The solution was added while stirring the solution in the part A with a homogenizer in the part C, and then the solution was emulsified by adding the solution in the part D. The mixture was cooled, and part B was added thereto at about 50℃and dissolved by stirring.
Example 67 skin Care cream
/>
/>
/>
(preparation method)
Part a was heated to about 70 ℃ to dissolve. And uniformly dissolving the part B. Part C was heated to about 70℃to disperse it. While stirring with a homomixer at about 70 ℃, part A was gradually added to part C to emulsify the mixture, and after cooling to about 40 ℃, part B was added to uniformly mix the mixture.
Example 68 hand cream
/>
(preparation method)
The parts B and C were heated to about 80℃to dissolve the same. The part A was weighed into a separate vessel, heated to 100 to 120℃and gelled transparently, cooled to 80 ℃. Part B was added to part A with stirring, and part C was further added to emulsify the mixture. After mixing well, cool to about 40 ℃.
Example 69 cleansing gel
(preparation method)
Part a was heated to about 80 ℃ to dissolve. Part B was warmed to about 80 ℃. Part B was added slowly to part a with stirring, mixed and cooled to 40 ℃.
Example 70 facial cleanser
/>
(preparation method)
Part a was heated to about 80 ℃ to dissolve. Part B was warmed to about 80 ℃. Part B was added slowly to part a with stirring, mixed and cooled to 40 ℃.
Example 71 shower gel
/>
(preparation method)
The whole ingredients are heated at about 80 ℃ and stirred and mixed uniformly.
Example 72 silicon-free shampoo
/>
(preparation method)
The whole ingredients are heated at about 80 ℃ and stirred and mixed uniformly.
Example 73 leave-in hair Care
/>
(preparation method)
Part C was dispersed uniformly and warmed to about 80 ℃. Next, part a was heated to about 80 ℃ to be dissolved. Part A was added to part C with stirring, and after mixing well, it was cooled to about 40 ℃. Then, the portions B were added and mixed uniformly.
Example 74 shampoo for scalp
/>
(preparation method)
Part B was heated to about 80 ℃ to dissolve. The part A was weighed into a separate container, and heated to dissolve it. Part B was gradually added to part A, and the mixture was mixed uniformly, and part C was added at about 60 ℃.
Example 75 shampoo
/>
(preparation method)
The part A was mixed well at about 80 ℃. The separately weighed part B was heated to about 60 ℃ and mixed well. Part B was added slowly while stirring part A, and after mixing well, it was cooled to about 50 ℃. Further adding part C and mixing uniformly.
EXAMPLE 76 lipstick
/>
(preparation method)
Heating and melting all the components, and mixing uniformly.
Example 77 foundation
/>
(preparation method)
Stirring all the components at high speed, and mixing uniformly.
EXAMPLE 78 solid powdered foundation
(preparation method)
Mixing part A by heating. The part B was weighed in a separate container and mixed and dispersed. And adding the part A into the part B, and uniformly mixing.
Example 79 liquid foundation
(preparation method)
The part A is heated and dissolved, and the part B is heated and uniformly mixed and dispersed in the part A (part D). The C part was heated and dissolved, and the C part was added to the D part with stirring, emulsified, and cooled to about 40 ℃.
Example 90 Sun protection cosmetic
/>
(preparation method)
And heating and dissolving the part A to uniformly disperse the part A. To this, a substance for dissolving the B part by heating was added, and the mixture was emulsified and dispersed by using a homogenizer, and the mixture was stirred and cooled to room temperature.
Example 91 Sun protection cosmetic
/>
(preparation method)
So that the A part is uniformly dispersed. The parts B and C were dissolved by heating at about 70 ℃. After part A was gradually added to part B, part C was gradually added to emulsify the mixture. While stirring and cooling, part D was added at 45℃and stirred.
Example 92 antiperspirant
(preparation method)
Heating and melting all the components, and mixing uniformly.
Cosmetics containing the components (A) to (D) of the present invention described below were prepared. The obtained cosmetic has excellent moisture retention and penetration feeling, and can prevent fine wrinkles and rough skin, and make skin look plump and bright.
Example 93 moisturizing lotion
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-cooled C part was added to form a uniform solution.
Example 94 moisturizing lotion
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then dispersed using a high-pressure emulsifying machine (MIZUHO industrial high-pressure microfluidizer). After cooling, the pre-cooled C part was added to form a uniform solution.
Example 95 moisturizing lotion
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-cooled C part was added to form a uniform solution.
Example 96 moisturizing lotion
(preparation method)
The parts A and B were heated to 70℃respectively, and the part A was added to the part B while stirring with a stirring blade (500 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-cooled C part was added to form a uniform solution.
Example 97 moisturizing lotion
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then dispersed using a high-pressure emulsifying machine (MIZUHO industrial high-pressure microfluidizer). After cooling, the pre-cooled C part was added to form a uniform solution.
Example 98 whitening lotion
(preparation method)
Mixing part B to prepare a viscous liquid. The portions A and C were heated to 70℃respectively, and the portion A was added to the portion C with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-mixed part B was added to form a uniform solution.
Example 99 whitening toning lotion
/>
(preparation method)
Mixing part B to prepare a viscous liquid. The portions A and C were heated to 70℃respectively, and the portion A was added to the portion C with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then, after cooling, the pre-mixed part B was added to form a uniform solution.
Example 100 gel toner
/>
(preparation method)
The part A is heated to about 70 ℃ and is evenly mixed and dispersed. Mix part C and stir thoroughly and then warm to about 70 ℃. Mixing part B with stirring paddle to obtain mixed solution. Part C was added to part A, stirred at about 70℃using a homomixer, cooled to 40℃and the mixture of part B was added.
Example 101 whitening emulsion
/>
(preparation method)
The portions A and E were each heated to about 70℃to dissolve. Stirring part B to obtain viscous liquid. Heating part C to about 70deg.C, and mixing and dispersing. After part A was added while stirring part C with a homogeneous disperser, part E was added while stirring. The part D and the part B were added at about 50℃and dissolved by stirring.
Example 102 skin care cream
/>
/>
(preparation method)
Mixing part A and part C respectively, heating to about 70deg.C, and dissolving and dispersing uniformly. Mixing part B, and stirring to obtain viscous liquid. The emulsion was obtained by adding part A to part C while stirring with a homomixer. After cooling, part B was added at about 50 ℃, stirred, and cooled to about 40 ℃.
Example 103 face washing foam
/>
(preparation method)
Part a was heated to about 80 ℃ to dissolve. Part B was warmed to about 80 ℃. Part B was added slowly to part a with stirring, mixed and cooled to 40 ℃.
Example 104 shampoo for scalp
/>
(preparation method)
Part B was heated to about 80 ℃ to allow uniform dissolution. The part A was weighed into a separate container, and heated to dissolve it. Part B was gradually added to part A, and the mixture was mixed uniformly, and part C was added at about 60 ℃.
Example 105 leave-in hair conditioner
/>
(preparation method)
Part C was heated to about 80℃to dissolve it. Part a was then heated to about 80 ℃ to dissolve. Part A was added to part C with stirring, and after mixing well, the mixture was cooled to about 40 ℃. Then, add part B and mix well.
Example 106 Hair care spray
/>
(preparation method)
The portions A and B were heated to 70℃respectively, and the portion A was added to the portion B with stirring by a homomixer (7000 rpm) to prepare an aqueous dispersion. Then dispersed using a high-pressure emulsifying machine (MIZUHO industrial high-pressure microfluidizer). After cooling, the pre-cooled C part was added to form a uniform solution.
Example 107 Sun protection cosmetic
/>
(preparation method)
The part A is evenly mixed and dispersed. The parts B and C were each heated to about 70℃to dissolve. After part B was gradually added to part a, part C was gradually added to emulsify the mixture. While stirring and cooling, part D was added at 45℃and stirred.
In the above formulation, the details of the components described by the product names are as follows.
IS: diisostearic acid dimer dioleyl ester
Is (1) LUSPLAN PI-DA: dimer dilinoleate di (isostearyl/phytosterol)
Is (1) LUSPLAN DD-DHR: dimer dilinol hydrogenated rosin ester condensate
Is (1) LUSPLAN DD-DA 5): dimer dilinoleate
Is (1) LUSPLAN DD-DA 7): dimer dilinoleate
Is (1) LUSPLAN SR-DM 4): dimer dilinoleate, glyceryl tri (caprylic/capric) ester
R, inulin-SC: inulin
Is a NanoRepair-CMC: composition containing quaternary ammonium salt-18, quaternary ammonium salt-33, cholesterol, ceramide 2, ceramide 3, ceramide 6II and PG
Neosolue-Aqulio: bis-diethoxydiglycol cyclohexane dicarboxylic acid ester
neoglue-Aqua: (eicosanedioic acid/tetradecanedioic acid) polyglycerol-10, glycerol
neocorrect-AquaS: (eicosanedioic acid/tetradecanedioic acid) polyglycerol-10, glycerol
Neosol-dimm: malic acid diisostearate
neosol-MP: methyl amyl dipivalate
Neosolue-DE: diethylpentanediol dipentamate
Plandol-H: dimerized dilinoleate (phytosterol/isostearyl/cetyl/stearyl/behenyl)
Plandol-S: dimerized dilinoleate (phytosterol/isostearyl/cetyl/stearyl/behenyl)
Plandol-G: dimer dilinoleate bis (behenyl/isostearyl/phytosterol)
Plandol-DP: didiglycerol polyacyl adipate-2
Plandol-ISS: isostearic acid plant sterol ester
Plandol-SUN: sunflower seed oil fatty acid phytosterol ester
(Plandol-MAS): queen oil fatty acid plant sterol ester
plandol-LG 1: lauroyl glutamic acid di (phytosterol/octyldodecyl/behenyl) ester
plandol-LG 2: lauroyl glutamic acid di (phytosterol/octyldodecyl) ester
plandol-LG 3: lauroyl glutamic acid di (phytosterol/octyldodecyl/behenyl) ester
plandol-LG 4: lauroyl glutamic acid di (phytosterol/octyldodecyl/behenyl) ester
Phytocompo-PP: hydrogenated lecithin and phytosterol
Phytocompo-C: hydrogenated lecithin, phytosterol, ceramide 2, ceramide 3, ceramide 6II
And (5) Phytopresome Asta: hydrogenated lecithin, phytosterol and astaxanthin
Phytopresome Lipo-Q: hydrogenated lecithin, phytosterol, lipoic acid and coenzyme Q10
Phytopresome Cera23: hydrogenated lecithin, phytosterol, ceramide 2, ceramide 3
Is a phytochrome MEL: glycolipid, hydrogenated lecithin, BG, purified water
Tremoist-TP: tremella polysaccharide
Tremoist-SL: tremella polysaccharide aqueous solution (1%)
And (b) LP70H: hydrogenated lysolecithin
Is shown in (1) Erucalactone MCT: gamma-docosactone, tri (caprylic/capric) glyceride
Is (1) Erucalactone DES): gamma docosaacttone, diethyl sebacate
Claims (6)
1. A composite, characterized in that:
which is used for preparing an emulsified or solubilized composition obtained by removing an organic solvent from a dispersion or solution in which the following components A1 to A3 are uniformly dispersed or dissolved in an organic solvent, and simultaneously precipitating the components A1 to A3,
a1: phosphatidylinositol,
A2: lecithin with phosphatidylcholine content of 50-99 wt%,
A3: sterols are used as the starting material for the composition,
the total content of the components A1 and A2 in the compound is 70 to 99 wt%,
the content of the component A3 is 1 to 30% by weight, and,
the weight ratio of the components A1 to A2 is 5: 95-30: 70.
2. the composite of claim 1, wherein:
the component A1 is a composition containing 40 to 75% by weight of phosphatidylinositol, which is obtained by a method comprising the following steps (1) to (3) in this order,
(1): a step of allowing a phosphatidylinositol-free phospholipase B having a substrate specificity to act on lecithin;
(2): extracting phosphatidylinositol with an organic solvent;
(3): and a step of precipitating and recovering phosphatidylinositol using a hydrophilic solvent.
3. The composite of claim 1 or 2, wherein:
the component A2 is a mixture of hydrogenated lecithin and non-hydrogenated lecithin.
4. The composite of claim 1 or 2, wherein:
also contains antioxidant substances as component A4,
the complex is used for preparing an emulsified or solubilized composition, which is obtained by removing an organic solvent from a dispersion or solution in which the components A1 to A4 are uniformly dispersed or dissolved in the organic solvent, and precipitating the components A1 to A4 at the same time,
The total content of the components A1 and A2 in the composite is 70 to 97 wt%, the content of the component A3 is 2 to 20 wt%, the content of the component A4 is 1 to 10 wt%, and the weight ratio of the components A1 and A2 is 5: 95-30: 70.
5. a cosmetic product characterized by:
a complex according to any one of claims 1 to 4.
6. An external preparation for skin, characterized in that:
a complex according to any one of claims 1 to 4.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018242080A JP7178257B2 (en) | 2018-12-26 | 2018-12-26 | Bioactive composition containing phosphatidylinositol |
JP2018-242080 | 2018-12-26 | ||
JP2019077573A JP7309428B2 (en) | 2019-04-16 | 2019-04-16 | Phosphatidylinositol-containing cosmetics or skin preparations for external use |
JP2019-077573 | 2019-04-16 | ||
JP2019-094291 | 2019-05-20 | ||
JP2019094291 | 2019-05-20 | ||
PCT/JP2019/035511 WO2020137017A1 (en) | 2018-12-26 | 2019-09-10 | Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation mitigator, wrinkle-ameliorating agent, complex, cosmetic and external preparation for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113226277A CN113226277A (en) | 2021-08-06 |
CN113226277B true CN113226277B (en) | 2023-12-01 |
Family
ID=71127127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980086762.9A Active CN113226277B (en) | 2018-12-26 | 2019-09-10 | Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20210107772A (en) |
CN (1) | CN113226277B (en) |
WO (1) | WO2020137017A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7354078B2 (en) * | 2020-09-29 | 2023-10-02 | 富士フイルム株式会社 | cosmetics |
CN111991278A (en) * | 2020-09-30 | 2020-11-27 | 珠海美逸生物科技有限公司 | Composition with skin barrier repairing effect and preparation method and application thereof |
JP7161073B1 (en) * | 2022-02-01 | 2022-10-25 | 大日精化工業株式会社 | Water-repellent cellulose beads, method for producing the same, and cosmetics |
CN115006309B (en) * | 2022-06-30 | 2023-09-22 | 山东福瑞达生物股份有限公司 | Microcirculation-improving whitening composition, microcirculation-improving whitening essence, and preparation methods and applications thereof |
CN116158534B (en) * | 2023-02-28 | 2024-05-14 | 仙乐健康科技股份有限公司 | High-load and stable protein liposome |
KR102630938B1 (en) | 2023-08-23 | 2024-01-31 | 에프아이씨씨주식회사 | Cosmetic compositions for skin regeneration, skin moisturization, and wrinkle improvement with improved skin permeability and component stability, and their manufacturing methods |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04149194A (en) * | 1990-10-08 | 1992-05-22 | Nippon Fine Chem Co Ltd | Lecithin-sterol complex and its production |
CN1266367A (en) * | 1997-06-10 | 2000-09-13 | 新时代株式会社 | Skin-lightening cosmetic |
JP2000300191A (en) * | 1999-04-16 | 2000-10-31 | Nisshin Oil Mills Ltd:The | Phytosterol-containing composition |
JP2004231544A (en) * | 2003-01-29 | 2004-08-19 | Nikko Chemical Co Ltd | Utilization of phospholipid as melamine production inhibitor |
CN1727351A (en) * | 2004-07-26 | 2006-02-01 | 商宗一 | Method for preparing compound of vegetative phosphatidylinositol in high purity |
CN101223274A (en) * | 2005-07-19 | 2008-07-16 | 旭化成制药株式会社 | Novel phospholipid processing agent |
JP2008260743A (en) * | 2006-08-03 | 2008-10-30 | Nagase Chemtex Corp | Nqo1 expression promoter |
WO2009028220A1 (en) * | 2007-08-28 | 2009-03-05 | Unitika Ltd. | Collagen production promoter |
ES2335636A1 (en) * | 2008-02-29 | 2010-03-30 | Lipotec, S.A. | Cosmetic of dermopharmaceutical composition of mixed micelles |
JP2014114291A (en) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | Cosmetic and skin external preparation |
FR3010306A1 (en) * | 2013-09-06 | 2015-03-13 | Lucas Meyer Cosmetics | COSMETIC COMPOSITION COMPRISING A LAMELLAR SYSTEM |
JP2018087148A (en) * | 2016-11-28 | 2018-06-07 | 日本精化株式会社 | COSMETIC CONTAINING γ-ORYZANOL |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60153938A (en) | 1984-01-23 | 1985-08-13 | Pola Chem Ind Inc | Preparation of novel liposome |
JPS60246305A (en) * | 1984-05-23 | 1985-12-06 | Nisshin Oil Mills Ltd:The | Cosmetic |
JP3557877B2 (en) | 1997-10-24 | 2004-08-25 | 株式会社コーセー | Cosmetics obtained by dispersing a lipid dispersion composition in an aqueous medium |
JP4933432B2 (en) * | 2005-07-19 | 2012-05-16 | 旭化成ファーマ株式会社 | New phospholipid processing agent |
JP5089887B2 (en) | 2006-01-23 | 2012-12-05 | 日本精化株式会社 | Bioactive substance-containing complex |
JP5561614B2 (en) * | 2008-03-04 | 2014-07-30 | ナガセケムテックス株式会社 | Hyaluronic acid extender |
JP2010120885A (en) * | 2008-11-20 | 2010-06-03 | Osaka City Univ | Collagen production promoter and skin cosmetic |
JP2011168541A (en) | 2010-02-19 | 2011-09-01 | Nagase Chemtex Corp | Nrf2 ACTIVITY ENHANCER, FOOD FOR Nrf2 ACTIVITY ENHANCEMENT, AND COSMETIC FOR Nrf2 ACTIVITY ENHANCEMENT |
KR20120077000A (en) | 2010-12-30 | 2012-07-10 | 한국전자통신연구원 | Online application system, apparatus by use of extended fields and method thereof |
US8800714B2 (en) | 2012-06-26 | 2014-08-12 | Hexcel Corporation | Structure with active acoustic openings |
JP2015027260A (en) * | 2013-07-30 | 2015-02-12 | 学校法人関西医科大学 | Producing method of phosphatidylinositol and composition comprising phosphatidylinositol |
JP2017178789A (en) * | 2016-03-28 | 2017-10-05 | 株式会社コーセー | Oil-in-water type emulsified composition |
-
2019
- 2019-09-10 CN CN201980086762.9A patent/CN113226277B/en active Active
- 2019-09-10 WO PCT/JP2019/035511 patent/WO2020137017A1/en active Application Filing
- 2019-09-10 KR KR1020217023151A patent/KR20210107772A/en not_active Application Discontinuation
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04149194A (en) * | 1990-10-08 | 1992-05-22 | Nippon Fine Chem Co Ltd | Lecithin-sterol complex and its production |
CN1266367A (en) * | 1997-06-10 | 2000-09-13 | 新时代株式会社 | Skin-lightening cosmetic |
JP2000300191A (en) * | 1999-04-16 | 2000-10-31 | Nisshin Oil Mills Ltd:The | Phytosterol-containing composition |
JP2004231544A (en) * | 2003-01-29 | 2004-08-19 | Nikko Chemical Co Ltd | Utilization of phospholipid as melamine production inhibitor |
CN1727351A (en) * | 2004-07-26 | 2006-02-01 | 商宗一 | Method for preparing compound of vegetative phosphatidylinositol in high purity |
CN101223274A (en) * | 2005-07-19 | 2008-07-16 | 旭化成制药株式会社 | Novel phospholipid processing agent |
JP2008260743A (en) * | 2006-08-03 | 2008-10-30 | Nagase Chemtex Corp | Nqo1 expression promoter |
WO2009028220A1 (en) * | 2007-08-28 | 2009-03-05 | Unitika Ltd. | Collagen production promoter |
ES2335636A1 (en) * | 2008-02-29 | 2010-03-30 | Lipotec, S.A. | Cosmetic of dermopharmaceutical composition of mixed micelles |
FR3010306A1 (en) * | 2013-09-06 | 2015-03-13 | Lucas Meyer Cosmetics | COSMETIC COMPOSITION COMPRISING A LAMELLAR SYSTEM |
JP2014114291A (en) * | 2013-12-13 | 2014-06-26 | Showa Denko Kk | Cosmetic and skin external preparation |
JP2018087148A (en) * | 2016-11-28 | 2018-06-07 | 日本精化株式会社 | COSMETIC CONTAINING γ-ORYZANOL |
Also Published As
Publication number | Publication date |
---|---|
CN113226277A (en) | 2021-08-06 |
WO2020137017A1 (en) | 2020-07-02 |
KR20210107772A (en) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113226277B (en) | Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation | |
US8101211B2 (en) | Compositions for retarding skin aging | |
US11547655B2 (en) | Use of an extract of the pericarp of Nephelium lappaceum for hydrating the skin and/or mucous membranes | |
JP2005220084A (en) | Acerola seed extract-containing composition | |
WO2004016236A1 (en) | Cosmetics | |
CN102440943A (en) | Composition for caring and improving aged or damaged skin | |
CN109414394B (en) | Composition for external use containing ascorbic acid and/or salt thereof | |
CN111166683A (en) | Fullerene anti-aging antioxidant beauty and skin care cosmetic and preparation method thereof | |
CN111032009B (en) | Skin whitening agent, external skin preparation for whitening skin, and method for whitening skin | |
JP2006328024A (en) | Skin care preparation | |
JP2002212087A (en) | Skin care preparation | |
JP2003063925A (en) | Skin care preparation | |
KR101862039B1 (en) | A cosmetic composition containing spicule powder and natural complex extract stabilized in nanoliposome | |
JP2016027023A (en) | Skin external preparations or cosmetics | |
JP2004210653A (en) | Skin care preparation for external use | |
JP2003160463A (en) | Skin care preparation | |
JP2006265120A (en) | Collagen synthesis accelerator | |
JP5398129B2 (en) | Skin metabolism promoter | |
JP2001163757A (en) | Preparation for external use for skin | |
JP2004131401A (en) | Skin cosmetic | |
KR20080059820A (en) | A anti-wrinkle agent containing camellia japonica oil | |
KR101448993B1 (en) | Pharmaceutical agent containing the Betula platyphylla Sukatchev var. japonica Hara extract as an effective ingredient and its use | |
WO1999017715A1 (en) | Extracellular matrix production promoter | |
Froiio et al. | Phytosomes as Useful Drug Delivery Systems for Cosmeceutical Application | |
JP2012171876A (en) | Whitening agent and melanin production inhibitor and whitening external preparation for skin or whitening cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |